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ABSTRACT 
Phosphate-metal complex formation is a naturally occurring toughening mechanism in 
underwater materials and has been incorporated into the synthetic hydrogel material discussed 
in this  dissertation. Polyphosphate hydrogels  were  loaded   with  Ca2+ which  crosslinks  OPO3
groups in the hydrogel which increase the initial modulus from 0.04 to 10.3 MPa and rupture at a 
critical force to dissipate strain energy and act as a sacrificial network to preserve the integrity of 
the hydrogel. Phosphate metal crosslinks are electrostatic domains that are easily recoverable, 
which adds to the durability and usefulness of the hydrogels. This toughening mechanism was 
borrowed from the underwater caddisfly larvae, which spin a tough, adhesive silk fiber to 
manufacture protective mobile cases from sticks, rocks and other advantageously gathered 
materials. The caddisfly silk also uses serial domains of phosphates crosslinked with Ca2+ to
increase modulus and produce strain induced yield, energy dissipation, and recoverability. 
In addition to metal ions, positively charged aminoglycoside antibiotics such as 
tobramycin can also be used as crosslinking agents. Due to electrostatically delayed diffusion, 
tobramycin is gradually released and exchanged with metal ions in biologically relevant Ca2+
and Mg2+ containing solutions. In the polyphosphate hydrogel system, tobramycin was included
with and without the presence of Ca2+ to form a hydrogel with the capability to sustain
tobramycin release for up to 70 days and totally eradicate pseudomonas aeruginosa biofilms 
within 48 h. In the case of hydrogels loaded with Ca2+ and tobramycin, the hydrogels retained
their toughness, and durability and thus may be used as structural materials in total joint
iv 
replacement to reduce incidence of infection. 
Complex coacervation is an alternative to the polyphosphate-tobramycin hydrogel 
system and occurs as a phase separation where a dense coacervate of polyphosphate and 
tobramycin is formed. The formation of clear, fluid coacervate phase is dependent on salt 
concentration and is maximized at ~1M NaCl. Polyphosphate-tobramycin coacervates have a 
sustained release assay for up to 60 days. Additionally, the coacervate can be resuspended into 
micro droplets by vortex and subsequently aerosolized for pulmonary delivery of tobramycin. 
Aerosolized coacervate is ideal for treating chronic pulmonary infection in cystic fibrosis. It could 
not only improve rates of pseudomonas aeruginosa infection but also reduce the number of 
required doses and thus improve patient compliance. 
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1.1   Biomimetic materials: reverse engineering nature 
Nature has excelled for millions of years at solving difficult problems using relatively 
few constituent materials, primarily comprising proteins and minerals.1 Central to many of 
these solutions is the complex, hierarchical structuring of natural materials.2 For example, the 
hierarchical arrangement of Nephila clavipes orb weaving spider silk, including a central core of 
parallel fibers encased in an outer skin layer, has been accredited with the silks remarkable 
strength.3 These biological structures have often provided inspiration for engineering challenges 
in the areas of architecture,4 aerodynamics,5 mechanical engineering5 and materials science.6 
Of particular interest is the innate ability for natural tissues to self-repair. This occurs not only 
on a molecular level with the inclusion of sacrificial reforming bonds, as observed in wood7 and 
bone where bonds are broken and reformed, but also at a cellular level where cells such as 
osteoblasts or fibroblasts lay down new tissue during repair processes.1 
Nature has adapted a simple arsenal of building materials into intricate solutions for 
complex problems. An underlying theme of the work presented here suggests that equally 
intricate answers to today’s problems can originate from mimicking simple structural 
components or design themes found in nature. 
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1.2   Aquatic caddisfly silk 
1.2.1 Caddisfly larva: the underwater architect 
The inspiration, behind the works presented, is nature’s underwater architect, the 
caddisfly.8 Caddisflies, order trichoptera, inhabit numerous fresh water habitats and mountain 
rivers and streams worldwide. Caddisfly lay their eggs underwater where new larvae live most of 
their yearly lives before pupation and brief mating and egg laying, Figure 1.1. The caddisfly larvae 
draw silk fibers from glands filled with fluid precursors, similar to related moth and butterfly 
larvae. The caddisfly silk is an adhesive fiber, used to assemble mobile protective cases and weave 
webs to gather food, Figure 1.1. This inventive use of silk has given rise to the widespread 
success of the species which is the second most abundant aquatic insect comprising 
approximately 14,291 different species. Details concerning the molecular makeup of caddisfly 
silk and its connection to mechanics and function has only recently been brought to light, in great 
part due to the efforts of Nicholas Ashton and Russell Stewart et.al.9–14   
 
1.2.2 Caddisfly silk: structure and function 
 
Caddisfly silk is a sticky, pressure sensitive tape comprised of a viscoelastic core encased 
in an adhesive outer coating. Silk attributes are uniquely derived from either the fibrous core or 
the adhesive outer layer, Figure 1.2. The fiber core imparts mechanical strength from multiple 
sub-fibers which are axially aligned, similar to other natural silks from moths, butterflies or 
spiders. The adhesive component is vital to full functionality as a binding substance for caddisfly 
cases. Inspiration for a biomimetic material was mechanically based, and thus, obtained solely 
from the structural core portion of the silk and not the outer adhesive layers. 
The primary component of the silk core as determined through quantitative PCR is the 
protein H-fibroin, Figure 1.3.14 H-Fibroin is highly repetitive and has up to 35 mol% of the amino 
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acid residues charged including Glu, Asp, Arg, and Lys. Additionally, approximately 15.5 mol % of 
Ser are negatively charged via post-translational phosphorylation.15 In fact, the phosphorylation 
of Ser residues has been identified across a wide range of suborders and appears to be conserved 
across the species. Of particular importance is the conservation and repetitive nature of a 
specific residue sequence termed the (pSX)n domain where n is 4-6, X is typically aliphatic Val, 
Leu or Ile and pS is phosphorylated Ser.9 Comparable repetitive sequences, like the poly(GA) 
domains found in terrestrial moths or spider silks, have been directly linked to a structural role 
in forming antiparallel β-sheets.16 The (pSX)n domain in caddisfly silk has likewise been 
attributed formation of antiparallel β sheets.17,18 Stewart and Wang revealed the central role of 
Ca2+ crossbridging between dianioic-pSs in stabilizing an antiparallel structure in caddisfly silk. A 
model was proposed where 2 (pSx)n domains flanking a central Pro-Gly sequence leads to the 
peptide backbone folding back on itself with aliphatic residues stabilized due to hydrophobic 
effects and pS by Ca2+ crosslinking, Figure 1.4.9 The presence of these parallel beta sheet 
structures throughout the silk fibers has been shown to play a vital mechanical role in 
preserving the integrity and durability of caddisfly silk. 
Caddisfly silk exhibits various mechanical properties that are of interest for 
biomaterials. Principally, the silk displays striking toughness for a highly hydrated material, 
~66% water by weight. Caddisfly silk has an initial modulus of 86.5 +/- 19.2 MPa and work of 
extension to failure of 17.3 +/- 6.2 MJ m-3.19 Additionally, the silk displays a pseudo yield point, 
large strain hysteresis and energy dissipation. Following strain, the silk self recovers 100% of the 
mechanics within 120 m. Stewart and Ashton et. al. presented a convincing case that directly 
links the Ca2+ and phosphate crosslinked (pSX)n domains with silk modulus, pseudo yielding 
behavior and spontaneous self-recovery following strain.9,10,12 Through the use of a custom 
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novel micro- materials testing system, single silk fibers were strained in tension allowing for the 
connecting of caddisfly silk micro-structure with mechanics. By removing Ca2+ with EDTA the 
native silk showed a reduction of initial modulus and complete loss of yielding behavior, Figure 
1.5. By the same token, the initial modulus and stress required for yield could be modulated by 
exchanging Ca2+ with other di or tri-valent metal ions.9 A trend emerged linking increased 
modulus, yield stress, and peak stress with increasing electronegativity.12 The yielding behavior 
and self-recovery was attributed to the reversible nature of the metal-phosphate bonds and a 
viscous unravelling of the (pSX)n domains that would reform as guided by an elastic recoiling 
force. 
In nature, the caddisfly silk works to dissipate impact energy to maintain the structural 
integrity of the case while the complete recovery leads to long term durability. These mechanical 
properties are desirable for translation into hydrated but tough prosthetic biomaterials and 
served as an inspiration for the development of caddisfly mimetic hydrogel. 
 
1.3   Double network hydrogels 
 
1.3.1   Evolution of hydrogels: from single to double networks 
 
Hydrogels are three dimensional polymer networks capable of retaining large quantities 
of water. The field of modern hydrogels began in the 1960s with the publications of Wichterle 
and Lim on a poly(2-hydroxyethyl methacrylate) hydrogel and subsequent hydrogel based 
contact lenses.20 These early hydrogels were synthesized from primarily hydrophilic monomers 
or polymers in the presence of multifunctional crosslinkers. The most commonly used hydrogels 
were poly(2-hydroxyethyl methacrylate) (pHEMA), poly(vinyl alcohol) (PVA), poly(ethylene 
glycol (PEG), and poly(acrylamide) (pAAm).21 Hydrogels are generally considered to be 
biocompatible due to the high water content and similarities to natural tissues, a motivating 
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factor in the exponential growth of the field over the last few decades.22 
Following the early pioneering work into simple, water swollen hydrogel networks, 
there was a shift in the 1970s toward more complicated, environmentally responsive hydrogels. 
These smart hydrogels undergo swelling changes facilitated by external stimuli including pH, 
temperature, ionic strength, solvent type, electric or magnetic fields, light, pressure, and presence 
of chelating agents.23,24 A popular, widely studied responsive system has been the in situ 
forming systems of poly(N-isopropylacrlyamide) (pNIPAAm) which rely on hydrophobic 
interactions to set the gel with increased temperature.21 Hybrid hydrogels consisting of 
synthetic materials and biological macromolecules or synthetic peptides have exploited the 
biocompatibility of the traditional hydrogel network and functionality from the bio-
macromolecules for an overall synergistic effect.24 For example, Gallot et. al. prepared di-block 
copolymers of polystyrene and poly(benzyloxycarbonyl-L-lysine) or poly(benzyl-L-glutamate) 
peptides which induced formation of lamellar structures which was subsequently linked to 
peptide secondary structures.25 Environmentally responsive hydrogels have been applied to a 
variety of applications including tissue engineering, biosensors and microfluidics.24 However, in 
many instances the weak mechanical nature of hydrogels has limited their use to drug delivery. 
The current arsenal of hydrogel materials are collectively weak and brittle, which has led to 
attempts to strengthen hydrogel materials for use as implantable prosthetic biomaterials. In 
contrast, natural tissues such as tendons, ligaments, muscle, and cartilage are highly hydrated 
(30- 80% water), soft materials but are also tough and capable of load bearing or shock 
absorption.26 The lack of strength in traditional hydrogels may be a result of the low density of 
polymer chains, limited friction between the chains and the inhomogeneous structure which 
concentrates stress around defects and promotes facture propagation.26 Some efforts to make 
the hydrogel structure more homogeneous have included a tetra-PEG hydrogel made from 
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tetrahedron type monomers, which use a slide-ring structure with mobile crosslinking 
points.27,28 Composite hydrogels of NIPAM and inorganic clay have also been shown to have 
improved toughness over single network systems.29 An alternative and increasingly widespread 
approach for toughened hydrogels involves incorporation of multiple network structures, 
termed double network (DN) hydrogels. 
Early DN hydrogels as reported by J.P. Gong et.al. were a tightly crosslinked rigid poly(2- 
acrylamido-2-methylpropanesulfonic acid) (PAMPS) network interpenetrating within a second 
loosely crosslinked pAAm network.30 These hydrogels exhibited both a high modulus from the 
rigid network with the extensibility of the loosely crosslinked network. This combination of 
increased modulus (0.1 – 1 MPa) and extensibility (1000-2000%) resulted in significantly higher 
tearing fracture energy (100-1000 J m-2), or toughness. During cyclical strain, energy is 
dissipated through chemical breakdown of polymer chains in the rigid or sacrificial network 
leading to accumulation of damage and a loss of toughness over time.19 To counteract fatigue 
related failure in early DN hydrogels, a multitude of creative approaches replaced the covalent 
linkages in one network with reversible non covalent bonds. Jie Zheng et. al. polymerized Agar 
and pAAm to create a DN hydrogel with a covalently linked pAAm network and sacrificial agar 
network with physically entangled helix bundles.31 Haque and Gong et. al. used a PDGI/pAAm 
hydrogel with stacked lipid-like bilayers as a sacrificial domain with excellent self-recovery.32 Bai 
and Lu et. al. produced a similar effect in a PAN/PMPC hydrogel with CN dipole moieties which 
interact to form the sacrificial network.33 Sun and Gong et. al. crosslinked cationic sodium p-
styrenesulphonate (NaSS) and anionic 3-(methacryloylamino)propyl-trimethylammonium 
chloride (MPTC) monomers to form a hydrogel with both covalent linkages and ionic crosslinks 
of varying strength, leading to recoverable yield.34 Other hydrogels have used charged moieties 
crosslinked with positively charged metal ions leading to increased modulus, toughness and 
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recoverability. Sue et. al. crosslinked carboxyl groups with divalent Ca2+ while Shull et. al. 
investigated a wider variety of divalent metals including Ca2+, Zn2+, Ni2+, Co2+, and Cu2+.35,36 
Shull et. al. concluded that different metal ions resulted in bonds of varying strength with the 
transition metal ions creating stronger ionic bonds than Ca2+, which was postulated to interact 
electrostatically.36 While a more complex bonding method related to d-orbital configuration 
was expected for certain transition metals the authors stopped short of a discussion into 
coordination bonding, which will be discussed in Chapter 2.36 
 
1.3.2    Intersection of caddisfly silk and double network hydrogel design 
 
While there have been great strides in increasing the strength and durability of 
hydrogels by incorporating a reversible sacrificial domain into DN hydrogels the modulus, 
toughness and recoverability falls short of the mechanics of the natural underwater caddisfly 
silk, Table 1.1. It is noteworthy to state that while some of the DN hydrogels in Table 1.1 have 
impressive strength, this toughness is only academic and occurs as a result of 100s to 1000s of 
percent extension at failure, an event not experienced in vivo. The motivation behind Chapter 2 
was to reproduce the mechanics observed in caddisfly silk, within a synthetic caddisfly mimetic 
hydrogel by the simple inclusion of phosphate side chains within a pAAm network.19 
 
1.4   Impact of biofilms and infection 
 
1.4.1 Expanding the functionality of caddisfly inspired hydrogels 
 
Modern biofilm theory can be traced to the work of J.W. Costerton beginning in 1978.37 
His basic theory was a culmination of observations and works suggesting that bacteria will 
preferentially adhere to surfaces forming complex colonies. By 1982, this phenomena was shown 
to be true for medical device surfaces, as illustrated in a case study by T. Marrie M.D. and J.W. 
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Costerton involving a pace maker contaminated with Staphylococcus aureus biofilm.38 Two 
years later, A Gristina M.D. and J.W. Costerton reported a similar incidence in several 
orthopedic implants.39 In an effort to expand the function of a caddisfly inspired DN hydrogel, 
Chapter 3 will present the results of loading poly-cationic tobramycin antibiotic into a 
polyphosphate hydrogel. Antibiotic-loaded DN hydrogels have the potential to prevent initial 
infection as a component of implantable or invasive medical devices or as a prophylactic to 
combat difficult infections such as those involving biofilms. 
 
1.4.2 Characterization of biofilms and antibiotic resistance 
 
The biofilm is an exopolysaccharide matrix secreted by adhered cells which increases 
antibiotic resistance by up to 1000 fold.40–42 Early observations by Lawerence et. al. used 
scanning confocal laser microscopy to reveal complex biofilm structure including large plumes 
and channels, hypothesized to transport nutrients throughout the biofilm and improve 
survivability.43 These features can be clearly identified in SEM images of P.aeruginosa biofilms in 
Figure 1.6. 
Some resistance may stem from frustrated penetration of antibiotic into the biofilm, in 
the case of positively charged aminoglycosides absorption to negatively charged biofilm 
components will reduce effectiveness.44,45 Slowed diffusion of aminoglycosides would seem to 
be a short-term problem as eventually all binding sites would be occupied and lead to a 
restoration of diffusion, although some authors have argued that slowed diffusion may 
accentuate an enzymatic inactivation of the antibiotics.40,41 
While the three-dimensional (3D) biofilm structure and potential reduction in diffusion 
are factors in antibiotic resistance they do not explain why even after eventual saturation of the 
biofilm with antibiotics there is ineffective eradication of bacterial cells. Multiple authors have 
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revealed a significant nutrient and oxygen gradient across the biofilm.46,47 Oxygen levels and 
protein synthesis are directly linked to metabolic activity in the bacterial cells with only 
metabolically active cells having normal antibiotic susceptibility.48,49 Near the biofilm surface, 
bacteria remain in an aerobic metabolic state and are readily killed with chemotherapy. In 
contrast, bacteria in the biofilm interior transition to an anaerobic metabolic state, with far less 
susceptibility to aminoglycoside antibiotics.46,47 
Along with nutrient driven metabolic changes, it is known that some subset of the 
population (~1%) will experience a phenotypic change resulting in immunity to antibiotics. This 
phenomena was first observed by Joseph Bigger, an army doctor in World War 2.50 After 
observing reoccurrence of infections following penicillin treatment, he isolated a staphylococcal 
subset in the lab resistant to penicillin. After culturing this subset and subsequent exposure to 
penicillin there was no increase in the percentage of surviving bacteria. He concluded that the 
resistance was not due to mutation and termed these survivors “persistors.” It is thought that 
these persister cells are used to reseed the colony following catastrophic events such as 
exposure to antibiotic treatment.51 
Biofilm eradication becomes more complex when addressing long term infections, like 
those observed in cystic fibrosis-related chronic pulmonary infection. There has been observed 
genetic adaptation in chronic infections over several years which leads to a loss of virulence 
factors. While these factors are important for initial invasion it has been postulated that these 
factors are also ligands for the immune system and the subsequent loss may yield a more 
robust population.52 In addition, these mutations may represent a symbiotic step in preserving 
the host organism as well as a decreased need to injure the host to generate nutrients. The 




1.4.3 Impact on medical devices and orthopedics 
 
Half of the 2 million cases of nosocomial infections in the United States are credited to 
indwelling devices.53 The bulk of these infections occur in either cardiovascular or orthopedic 
devices with associated direct medical costs of $3 billion annually.54 It has been predicted that 
device related infections will continue to rise; a result of increased biomedical implants (14% 
increase in knee and hip replacement from 1996 to 2001) and an aging population with increased 
life expectancy.54 The occurrence of infection has been attributed to the presence of a host 
derived layer of adhesive proteins such as fibrinogen and collagen followed by adherence of 
planktonic bacterial cells and formation of biofilm in and around the implanted device.53 The 
process of protein absorption has been well characterized by Andrade and Hlady et. al. and occurs 
immediately upon implantation.55 A survey of nosocomial infection and data from the United 
States Center of Disease Control (CDC) estimate that 65% of infections in the developed world 
arise from biofilm formation.56 It is important to note an alarming trend in device related 
infection with the emergence of resistant strains of bacteria and a reduction in the 
effectiveness of current antimicrobial strategy. 
 
1.4.4 Emergence of resistivity: an ongoing concern 
 
Following the widespread use of antibiotics in the 1940s each sequential decade brought 
the emergence of drug resistant strains, including strains with resistance to multiple drugs.57 
Drug resistance first appeared in hospitals where antibiotics were used frequently. Sulfonamide 
resistant Streptococcus emerged from military hospitals in the 1930s and penicillin-resistant 
Staphylococcus aureus arose from London hospitals shortly after penicillin’s introduction in the 
1940s.58–60 Fueled by increases in antibiotic use, the rise of resistant strains became more and 
more frequent. The 1980s saw a re-emergence of tuberculosis in multidrug resistant strains.61 
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Currently in the United States 40-60% of S. aureus nosocomial infections are methicillin –
resistant (MRSA).58,62 There have even been a handful of isolated cases of MRSA with resistivity 
to vancomycin, that until the expansion of new drugs daptomycin and linezolid, was a last line 
of defense. P.aeruginosa strains have been found that are resistant to most anitbiotics and have 
resulted in deaths, especially in immune-compromised patients.58,63,64 There are indications 
that biofilms may facilitate development of resistant strains. Bacterial strains can experience a 
gradual increase in resistance as the use of antibiotics suppresses susceptible strains while 
selecting for resistant cells. Additionally, drug resistant genes can be shared between bacterium 
through mechanisms including plasmids, bacteriophages, naked DNA or transpoons.57,58 These 
mutations can directly lead to mechanisms of resistance such as antibiotic efflux pumps, and 
antibiotic degrading or altering enzymes. In bacteria dense communities like biofilms, the 
spread of resistant genes is promoted. In 1999, Hausner and Wuertz used fluorescent labeling 
and confocal laser scanning microscopy to quantitatively show that P.aeruginosa in biofilms 
could transfer plasmids between cells 1000 times faster than planktonic cells.65 This ongoing 
concern over the spread of resistant organisms will be addressed in Chapters 3 and 4, where a 
localized sustained tobramycin release profile could maintain high local drug concentrations and 
speculatively reduce the risk of creating resistant strains. 
 




1.5.1 Cystic fibrosis leads to chronic pulmonary infection with  biofilm presence 
 
Cystic fibrosis (CF) is a life shortening genetic disease, with a higher prevalence in 
Caucasian populations.66 Mutation occurs in the cystic fibrosis transmembrane conductance 




transport across epithelial mucosal cells leading to NaCl and water imbalance and consequently 
viscous, sticky mucus excretions.67–70 Associated complications include: liver disease, pancreatic 
insufficiency, diabetes, and chronic lung infection, the leading cause of CF related death.66,71,72 
The effect of CF on the lungs is profound and disrupts normal lung immune response. 
The primary factor reducing the pulmonary immune response is unclear but is speculated to 
multifaceted.  Frustrated  mucosal  clearance from  the airways  provides an ideal niche  for  the 
invasion of opportunistic bacteria. Recent publications by Mike Welsh et. al. have revealed a 
link between the absence of CFTR protein with low secretion of HCO3 which, in the presence of 
continued proton release, results in lower pH or acidification of the surface airway liquid.73 This 
acidification has been proposed as an important factor for explaining reduced effectiveness of the 
host immune system.73 The combination of reduced hydration in mucus, lack of mucosal 
clearance, surface airway acidification, and formation of biofilms illustrates the complex 
environment that has resulted in the presence of chronic airway infection in cystic fibrosis. 
Most CF patients experience acute infection of gram-negative Pseudomonas aeruginosa which 
eventually progresses into chronic biofilm based infection in almost all cases.52 Despite ongoing 
research and clinical efforts to eradicate chronic infection in CF patients, there is to date no 
successful solution for eradicating chronic P.aeruginosa infection.52,74,75 
State of the art care guidelines for P.aeruginosa infection includes inhaled tobramycin 
(aminoglycoside) for 28 day cycles.76 Accumulation of tobramycin on bacterial cell surface 
triggers energy dependent uptake into the cell, where subsequent binding to RNA prevents 
protein synthesis, resulting in cell death.77 While this approach has shown success in early acute 
infection, it is ineffective in terms of total eradication of chronic infection. Additionally, the 
burden of taking multiple doses per day for 28 day cycles, including the time to nebulize the 
drug and sanitize the equipment after every dose, leads to decreased patient compliance. This 
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is further exacerbated by additional time intensive tangential therapies including physical 
therapy and pharmaceutical treatments for inflammation of airways, mucolytics, digestion, 
diabetes, and liver disease. While these metrics are difficult to measure, the compliance rates 
for some treatments is estimated to be as low as 16-20%.78–81 
Chronic P.aeruginosa infection in CF airways presents an impactful opportunity for a 
sustained tobramycin releasing material. While Chapters 2-4 will focus on the application of 
bulk hydrogels, Chapter 5 will present the applicability of a micro-particle polyphosphate-
tobramycin material for pulmonary delivery of aminoglycosides. This is significant not only as a 
means of eradicating chronic infection, but also as a means of decreasing patient care burdens 
and improving compliance by reducing the number of required daily doses of tobramycin. 
 
1.5.2 The phenomena of complex coacervation 
 
Coacervation is a liquid-liquid phase separation in a colloidal system. The more 
concentrated colloid component is termed the coacervate while the other more dilute phase is 
the equilibrium solution. The coacervation process is entropically driven and has been 
associated with delocalization of counter ions from poly-cationic and poly-anionic components 
to form a neutral “complex”.82 Coacervations derived from polyelectrolytes have thus been 
coined complex coacervations. 
The phenomena was first identified by F.W. Tiebackx in 1911 but not thoroughly 
investigated until 1929 when Bungenberg de Jong et.al. reported on a gum Arabic-gelatin 
coacervate.83,84,82 The first theoretical model for coacervation was proposed by J. Overbeek and 
M. Voorn in 1957.85 This model described complex coacervation as a competition between 
electrical attraction and accumulation of charged particles, based on Debye-Huckel equations, 
and an entropic dispersing force, based on the Flory-Huggins theory for entropy. Since its 
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publication, extensions have been made to the Voorn-Overbeek theory to better fit unique 
circumstances such as aggregation of soluble complexes and excess polyions.86–88 In a recent 
review of complex coacervation theory, Charles Sing compared Voorn-Overbeek and extensions 
with work by Borue and Erukhimovich involving random phase approximation (RPA) that 
describes a globular structure of coacervate droplets and subsequent aggregation.89 RPA theory 
predicts aggregation due to a tradeoff between increased hydration area and entropic release 
of counter ions. Sing also extended a comparison to include modern theories including 
complexation theory, field theory and molecular dynamic simulation.88 While Sing states that “a 
unified theory of complex coacervation is still missing,” it is evident that all theories point to a 
entropic driven process from release of counter ions and electrostatic interactions between 
polyelectrolytes.88 Work by Renko Vries et. al. described the physiochemical conditions for 
complexes to stay in solution.82 It was predicted that strong polyelectrolytes may form 
precipitates rather than liquid coacervate, charge balancing leads to maximum coacervate yield, 
and salt will have a dissociating effect on complex formation at both high and low 
concentrations.82 
 
1.5.3  Adapting coacervates for treatment of cystic fibrosis 
 
Stewart and Wang et. al. derived inspiration for a synthetic complex coacervate from 
naturally occurring underwater glue of the Sandcastle worm (Phragmatopoma californica).90 The 
sandcastle glue protein composition contains more than 50 mol % Ser and Gly residues, and 
thus has many negatively charged carboxyl groups (Gly) and over 90% of Ser residues 
phosphorylated. Elemental analysis revealed the presence of Mg2+ and Ca2+ at ratios of 0.6 
to 1.0 metals per phosphate respectively. Although the authors discounted the role of complex 
coacervation in the formation of sandcastle glue, it directly led to the use of synthetic glue silk 
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analogs for complex coacervation. 
The work with sandcastle glue analogs for underwater adhesives is similar to the 
exploration of caddisfly silk analogs for the purpose of designing a tobramycin releasing 
polyphosphate coacervate. Chapter 5 will illustrate the development of polyphosphate 
coacervates as a pulmonary drug delivery vehicle with sustained release of aminoglycosides. 
The application of which has great potential for addressing the problem of chronic pulmonary 
infection in CF patients. 
1.6    Motivation and rationale for the study 
Recent investigations into mechanochemical characterization of caddisfly silk as a 
unique underwater material is noteworthy. Caddisfly silk fibers are strong and dissipate large 
amounts of strain energy before completely recovery. The remarkable strength is particularly 
impressive for a highly hydrated material. Unfortunately, there is no current method for 
harvesting large quantities of natural caddisfly silk. Any impactful result of the caddisfly silk 
discoveries may necessarily arise from the development of a caddisfly silk analog that mimics 
the mechanochemical components of the natural silk. 
The short term motivation for the study is to view the caddisfly silk as a naturally 
occurring underwater hydrogel. From this vantage point it is reasonable to incorporate caddisfly 
silk components, primarily dense regions of phosphates crosslinked by divalent metals into a 
double network hydrogel. While recent strides in hydrogel design have addressed the 
mechanical shortcoming of traditionally weak and brittle hydrogels they fall well short of 
replicating the stiffness, strength and toughness of caddisfly silk, Table 1.1. The work presented 
here aims to advance the field of tough hydrogels through caddisfly inspired design principles. 
Additionally, the inclusion of caddisfly like features into a synthetic material serves as proof on 
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concept and confirmation for the explanations and hypothesis presented in the works of Russel 
Stewart and Nicholas Ashton. 
The study also aims to make new strides in controlled drug delivery. Incorporation of 
aminoglycoside antibiotics as electrostatic crosslinks and structural components of the hydrogels, 
pushes the boundaries of the current state of the art in drug delivery. Furthermore, there exists 
a gap in the literature in terms of hybrid hydrogels that combines toughening mechanisms with 
sustained drug elution. The motivation of this study is to fill that gap and provide a tough, highly 
hydrated material for use as structural biomaterials with the dual purpose of preventing and 
fighting infection. 
Over the long term it is hoped that these materials will eventually be used in new 
orthopedic implants like knee or hip arthroplasty with the ability to decrease incidences of 
infection. These materials may possibly serve a role in revision surgeries, where it may be 
necessary to eradicate an established infection. Tough, drug eluting hydrogels could also be 
used as surface coatings or materials for invasive devices such as stents, heart valves, vascular 
access lines, and catheters. 
Of particular importance is the potential use of this material in coacervate form as a 
pulmonary delivery system for tobramycin in CF patients. Almost all CF patients suffer from 
chronic and sometimes debilitating lung infection that leads to decreased lung function and 
ultimately death. To date, there is no known cure for CF or any successful method at eradicating 
chronic infection. It is the hope of this author that these new materials may provide a better 
platform for attacking chronic CF infection, while directly leading to better patient compliance 
and thus more promising clinical results. 
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PAMPS pAAm Interpenetrating Network (IPN) -- 21 MPa 98% None 80 
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e Gelatin IPN 21 MPa 3.8 MPa 28% None 91 
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Figure 1.1. Photographs of caddisfly insects A) Photograph of caddisfly larvae with rock case, 
collected from Red Butte Creek, Salt Lake City. B) Photograph of caddisfly larvae with case 








Figure 1.2. SEM image of caddisfly silk. Showing stitching pattern of caddisfly silk between 








Figure 1.3. Partial Hesperophylax sp. H-fibroin sequence. The continuous sequences are arranged 
to highlight the pattern of conserved D, E, and F subrepeats. The shared arginine-rich motif with 
a central proline is highlighted in gray. (pSX)n motifs are underlined. The hypothetical [(pSX)4]2 
β- hairpin sequence is highlighted in turquoise. (A) N-terminus. Bold italics indicates the secretion 
signal peptide. (B) C-terminus; * = stop codon. (C) Schematic representation of the irregularly 
repeating pattern of conserved subrepeats. This figure was published by Stewart et. al. and 







Figure 1.4. Hypothetical molecular structure of caddisflyH-fibroin β-domains and silk fibers. (A) 
Representative structure the D subrepeat [Ca2+(pSX)4]2 β-hairpin from cluster analysis of a 40 ns 
MD simulation. Ca2+ = blue spheres, Cl− = green spheres. (B) Representative structure after 10 ns 
of MD simulation of an extended β-sheet modeled with three antiparallel [Ca2+(pSX)4]2 β-hairpins. 
(C) Representative structure of a three- sheet β-domain stabilized through alternating pS-Ca2+ 
bridged interfaces and hydrophobic interfaces. Calculated dimensions of the domains are 
indicated. (D) Macroscale nanocomposite fiber model: semicrystalline Ca2+-stabilized, pS-rich β- 
domains (turquoise) form interfiber cross-links connected by amorphous regions (black). (E) The 
core of the silk fiber consists of 100−80 nm nanofibrils (turquoise) running parallel with the 
macrofiber axis. (F) The paired subfibers (turquoise) are fused together and have a thin, poorly 









Figure 1.5: Single caddisfly fiber mechanics. (A) Five fibers were stained to failure in 1 mM Ca2+ 
(green) or in 1 mM EDTA (blue). (B) Force−extension profiles of a single native fiber cyclically 
loaded 4 times to 0.5 in 1 mM Ca2+. The fiber was relaxed for 15 m between each strain cycle. 
(C) Green: force−extension profile from the third cycle of a single fiber cyclically loaded three 
times to 0.5 in 1 mMCa2+. Red: force−extension profile of a fiber cycled to 0.5 after 30 m in 1 
mM EDTA. Blue: force−extension profile 24 h after replacing EDTA with 5 mM Ca2+ and cycling to 







Figure 1.6 SEM images of pseudomonas aeruginosa biofilms. Biofilms were grown with a 
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Figure 3.S1 A) H1 NMR spectra for MOEP monomer. B) P31 NMR spectra for MOEP monomer. C) 
H1 NMR spectra for pPEMA-MA polymer 
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Figure 3.S2 Titration of pPEMA-pAAm hydrogels with NaOH. 
CHAPTER 4 
TOBRAMYCIN RELEASE FROM CADDISFLY INSPIRED TOUGH CA2+/POLYPHOSPHATE 
DOUBLE NETWORK HYDROGELS 
4.1 Introduction 
Hydrogels are three-dimensional polymeric structures that retain large amounts of water 
and are currently employed as contact lens material, wound dressings, as scaffolds for tissue 
engineering, and as localized smart drug delivery materials.1,2 Localized controlled delivery 
systems are intended to deliver drugs at prearranged rates for targeted periods of time and 
maintain high local concentrations while limiting the adverse effects from high systemic doses. 
The first hydrogels were developed in the 1960s and were simple networks like poly(2-
hydroxyethyl methacrylate) (pHEMA) or poly(acrylamide) (pAAm).3 Drug release from these 
simple single network hydrogels is purely diffusion based, for example, a pAAm hydrogel was 
shown to release its entire payload of tobramycin within 24 h.4 However, more complex 
hydrogels have been adapted for in vivo use as controlled drug delivery materials with an ability 
to sustain drug release for much longer than 24 h.5 Some strategies for sustained release have 
included: modification of gel microstructure to reduce diffusion of large molecules,6–9 tying 
release to hydrogel degradation,10 degradable conjugation of drug to the hydrogel network,6,10–
12 externally triggered volume changes to control diffusion,8,9,13,14 diffusion restrictive thin 
surface coatings,7,8 and electrostatic binding of charged molecules.15–21 There is a particular need
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 for localized antibiotic drug release materials to both eliminate infection and avoid the pitfalls 
of traditional systemic delivery including organ toxicity, reduction of beneficial bacteria and 
overgrowth of resistant organisms such as Candida and Clostridium difficile.22 
While hydrogels are promising materials for controlled drug delivery their application as 
in vivo implantable materials is hindered by their weak and brittle nature. Incorporation of a 
sacrificial component into the hydrogel structure results in increased toughness and blunting of 
crack propagation as the sacrificial network breaks resulting in preservation of the other 
network and maintaining hydrogel integrity. Sacrificial domains have been integrated into 
hydrogel structure through the use of Interpenetrating networks (IPN) or inclusion of double 
networks (DN). An example of an IPN hydrogel uses a densely crosslinked network of 2-
acrylamide-2-methylpropanesulfonic acid interpenetrating within a sparsely crosslinked 
acrylamide network.23 IPN hydrogels have the compressive strength of the densely crosslinked 
network in combination with the elasticity and extensibility of the loosely crosslinked network. 
During strain one network acts as an energy dissipating sacrificial domain, however 
accumulating damage in the sacrificial network reduces the long term usefulness of these IPN 
hydrogels. More complex hydrogels use covalent and noncovalent crosslinking to form a DN 
where the noncovalent crosslinked network acts as a reversible sacrificial domain to increase 
toughness while preventing damage accumulation through the reformation of noncovalent 
crosslinks. Examples of DNs include physical crosslinks,24,25 hydrophobic bilayers,26 dipole–dipole 
coupling,27 electrostatic bonding between oppositely charged functional groups,28 metal ion 
complexes,29–31 controlling network structure and pore alignment32, and reversible polymer 
absorption to solid particles.33 By combining toughness with reversible crosslinks, DN hydrogels 
have emerged as a promising biomaterial compared to weak and brittle single network 




Caddisfly insects (order Trichoptera) have adapted a unique underwater silk that acts as 
a naturally occurring tough double network hydrated material. Caddisfly larva reside 
underwater in freshwater streams and lakes worldwide.34 The success of this order in 
maintaining a diverse population across multiple freshwater habitats derives from a unique use 
of adhesive and tough underwater silk. Caddisfly silk comprises a viscoelastic silk core encased in 
a sticky peripheral layer allowing the larvae to construct protective underwater habitats from 
leaves, sticks, or stones. The viscoelastic properties of the silk has been associated with 
repetitive blocks of highly phosphorylated residues in the H-fibroin protein structure, the major 
protein constituent of the silk core.35 When the silk is excreted in freshwater habitats the 
natural calcium present in freshwater sources crosslinks the phosphates inside the silk forming 
serial β-sheet domains of calcium crosslinked with phosphates. These phosphate-calcium 
domains rupture in response to stress leading to a pseudo-yield behavior that is recovered as 
phosphate and calcium domains reform in response to an elastic recoiling force. The tensile 
modulus of caddisfly silk ranges from 80-140 MPa with a strength of 10-20 MPa at 80% 
elongation and near 100% recovery of modulus and hysteresis within 120 m.36,37 The modulus 
and toughness of the silk can be modified by exchanging calcium with other divalent metal ions 
further supporting the link between phosphate-metal crosslinks and observed mechanics.38  
Other synthetic DN hydrogels have been improved by replacing the covalently linked 
sacrificial network with numerous types of reversible non-covalent crosslinks. These have 
included physical crosslinks,24,25 hydrophobic bilayers,26 dipole–dipole coupling,27 electrostatic 
bonding between oppositely charged functional groups,28 metal ion complexes,29–31 controlling 
network structure and pore alignment32, and reversible polymer absorption to solid particles.33 
By increasing toughness, DN hydrogels have emerged as a promising biomaterial compared to 
58 
 
weak and brittle single network hydrogels and can expand the usefulness of hydrogels as in vivo 
controlled drug delivery materials.  
A biomimetic DN hydrogel was designed to derive toughness from phosphate-metal 
crosslinks, a common toughening component in natural materials such as caddisfly silk, spider 
fangs, stingers, and rag worm mandibles.37,39,40 The DN hydrogel was synthesized from 
copolymerization and crosslinking of a polyphosphate prepolymer (pPEMA-MA) and 
polyacrylamide (pAAm).41 The DN polyphosphate hydrogel was covalently crosslinked with bis-
acrylamide crosslinker and MA groups on the prepolymer with a second network being formed 
with the addition of divalent metal ions. The result was a viscoelastic phosphate-metal 
crosslinked network in combination with an elastic covalently linked pAAm network. The 
resulting mechanics were strikingly similar to the caddisfly silk, including increased modulus up 
to 34.2 +/- 2.5 MPa, and pseudo yield behavior as metal-phosphate domains ruptured during 
strain. Like the caddisfly silk, the polyphosphate DN hydrogels self-recovered up to 90% of the 
modulus and hysteresis within 30 min as metal-phosphate crosslinks were reformed under the 
restoring force from the elastic network.  
In addition to using phosphate metal complexes as a toughening component, the 
phosphate network can function as an aminoglycoside delivery vehicle by replacing divalent 
metals with polycationic aminoglycoside antibiotics.4 Tobramycin loaded polyphosphate DN 
hydrogels were capable of sustained tobramycin release for up to 60 days, a result of 
electrostatically reduced diffusion of tobramycin out of the hydrogel. The sustained release 
resulted in formation of zones of inhibition against Pseudomonas Aeruginosa (P.aeruginosa) for 
25 days and total eradication of P.aeruginosa biofilms within 72 h.  
Despite extensive investigation into hydrogels as both drug delivery vehicles and as 
tough materials for in vivo applications there is an absence of reported DN hydrogels with 
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mechanisms for both toughening and sustained antibiotic release. Presented here is the use of a 
dual purpose double network polyphosphate hydrogel capable of replicating the toughness seen 
in caddisfly silk through phosphate-Ca2+ crosslinking while simultaneously binding and slowly 
releasing tobramycin antibiotic for over 60 days. This dual mechanism allows for tough 
hydrogels that could not only be used as structural materials in orthopedics, vascular access 
lines and bandages but also prevent and eliminate infections during and after invasive medical 
procedures.    
 
4.2 Experimental section 
4.2.1 Materials 
Phosphorus(V) oxychloride, 2-hydroxyethyl methacrylate, triethylamine, and glycidyl 
methacrylate were purchased from Alfa Aesar (Ward Hill, MA). Methacrylic acid, 2,2’-azobis(2-
methylpropionitrile), acrylamide, N,N’-methylene-bisacrylamide, and N,N,N’,N’-
tetramethylethylenediamine were purchased from Sigma Aldrich (St Louis, MO). Ammonium 
persulfate, Orion Ionplus calcium standard, and A optimum results filling solution were 
purchased from Fischer Scientific (Pittsburgh, PA). Tobramycin (97%) was acquired from Acros 
Organics (New Jersey, USA).  
 
4.2.2 Synthesis of MOEP monomer and polyPEMA-MA copolymers 
2-(Methacryloyloxy)ethyl phosphate (MOEP) was synthesized as previously described 42. 
Briefly, phosphorus oxychloride (33.9 g, 220mmol) and hydroxylethyl-methacrylamide (HEMA) 
were mixed at a 0.7:1 molar ratio in dry toluene (480 mL) under argon. The reaction was stirred 
at 4°C and triethylamine (TEA) (77 mL) added in three increments over 10 m. Next the reaction 
was stirred at 22°C for 6 h under argon, then filtered to remove precipitated salt. The reaction 
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was cooled to 4°C before the addition of deionized water (480 mL), then stirred under argon at 
22°C for 12 h. The reaction was extracted twice with diethyl ether (100 mL) and the organic 
layers discarded. The aqueous layer was extracted using tetrahydrofuran (THF) and diethyl ether 
(1:2, 12 X 225 mL), then dried over anhydrous sodium sulfate before evaporating the solvent. 
Poly(phosphoethyl-methacrylate-co-acrylic acid) (pPEMA-AA) was synthesized by free 
radical polymerization of MOEP (85 mol%), and methacrylic acid (15 mol%) in methanol (12.5 mL 
mg-1 MOEP).  MOEP and methacrylic acid were degassed by bubbling with argon for 1 h, 
followed by addition of azo-bis-isobutyronitrile (AIBN, 4.5 mol%) at 55°C to initiate 
polymerization. The reaction was stirred for 15 h before precipitation with acetone, then 
dissolved in water (200 mL H2O per 17 g pPEMA-AA). Afterward, methacrylate groups (MA) were 
grafted onto the methacrylic acid sidechains with glycidyl methacrylate in 9-fold molar excess 
relative to the carboxylate sidechains. The methacrylated pPEMA-AA (pPEMA-MA) was adjusted 
to pH 7.3 with NaOH and purified by tangential flow filtration using a Millipore Pellicon 3 
cassette filter with an Ultracel 10 kD membrane. The polymer product was lyophilized, and 
stored at -20°C.  
The structure and composition of the monomer (MOEP) and polymers (pPEMA-MA) 
were verified by 1H and 31P NMR.4 The pPEMA-MA polymer contained 65 mol% phosphate 
sidechains, 12 mol% HEMA, and 23 mol% MA sidechains. The molecular weight (Mw) and 
polydispersity index (PDI) of pPEMA-MA were determined by size exclusion chromatography 
(SEC) on an Agilent Infinity 1260 HPLC system with a PL-Aquagel-OH Mixed-M column (8 µm, 
300x 7.5mm) column. The column buffer was 0.1 M NaNO3 / 0.01 M NaH2PO4, pH 8.0 with a 
flow rate of 1 mL m-1. The average Mm and PDI, 46 kg mol-1 and 1.67, respectively, were 
estimated using sodium polymethacrylic acid standards.  
MOEP;  1H NMR (D2O, 400 MHz); 5.9 (s, 1H), 5.5 (s, 1H), 4.2 (m, 2H), 4.0 (m, 2H), 1.7 (s, 3H).  
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  31P NMR (D2O, 400 MHz), 0.213 (s).  
pPEMA-MA; 1H NMR (D2O, 400 MHz); 6.1 (s, 1H), 5.6 (s, 1H), 4.2 (m, 2H), 4.1 (m, 2H), 3.5 (m, 
2H), 1.8 (t, 2H), 1.0 (s, 3H), 0.8 (s, 3H). 
 
4.2.3 Hydrogel synthesis: copolymerization of polyPEMA-MA and acrylamide 
Hydrogels were formed by free radical polymerization of the pPEMA-MA prepolymer 
with acrylamide (Aam) and N,N-methylenebisacrylamide (bis-Aam), a bifunctional crosslinker, in 
150 mM NaCl (Figure 4.1 A,B). The wt% of pPEMA-MA and AAm/bis-AAm were 6.5% and 1.0%, 
respectively. The molar ratio of AAm to bis-AAm was 60:1. Polymerization was initiated by 
adding 10% ammonium persulfate (APS) and tetramethylethylenediamine (TEMED) to final 
concentrations of 70 µg ml-1 and 2.4 µl ml-1, respectively. Following addition of APS and TEMED, 
250 µl aliquots were placed in wells of a 48 well plate with 200 µl of 2-propanol floated on top 
to limit oxygen exposure. After 90 m, polymerized hydrogel disks were removed and soaked in 
150 mM NaCl for 24 h to remove unreacted reagents. 
 
4.2.4 Determination of Ca2+ and tobramycin loading by measuring  
depletion in loading solutions 
Uniform 250 µl hydrogel discs were immersed in 150 mM NaCl and Ca2+ at molar ratios 
of 1.8, 0.8, 0.3 and 0.1 total Ca2+:OPO32-. Ca2+ loaded hydrogels were subsequently loaded with 5 
mM tobramycin and 150 mM NaCl adjusted to pH 7.7 with HCl for 12 h. Time lapse videos of 
hydrogel deswelling during Ca2+ and tobramycin loading were analyzed in Image J to measure 
hydrogel diameters. Isotropic shrinking was assumed to calculate volume changes from the 
diameter. Mechanical tests were performed both prior to and after loading with tobramycin. 
Total tobramycin concentrations in the hydrogels was determined by depletion of 
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tobramycin in the loading solution.  Tobramycin concentrations were measured colorimetrically 
using a Pyrogallol Red-Molybdate (PRM) assay for primary amines 43–45. A PRM solution was 
prepared by mixing 0.4 mL of 1.2 mg/mL pyrogallol red in methanol, 9 mL of a solution of 55 
mM succuinic acid and 4 mM sodium benzoate, and 0.04 mL each of 12 mM disodium 
molybdate and 261 mM sodium oxalate. Tobramycin containing samples (40 µL) were added to 
160 µl of the PRM solution in a clear 96 well plate. After 45 min at 22° C absorbance at 600 nm 
was measured in a Spectra Max M2 plate reader and compared to tobramycin standards.  
Total Ca2+ concentration was determined by depletion of Ca2+ in the loading solution. 
Ca2+ concentrations were measured using an Orion 9700 BNWP calcium selective probe paired 
with an Orion Dual Star meter from Fisher Scientific. A direct calibration curve of electrode 
potentials of standard solutions were measured and experimental solutions were compared to 
the linear range of the standard curve to determine concentration. Orion Ionplus calcium 
standard (0.1 M Ca2+) was diluted in 130 mM NaCl for the calibration curve and Orion A 
Optimum Results filling solution was used to fill the interior of the probe.  
 
4.2.5 Determination of release kinetics from Ca2+-tobramycin hydrogels 
Three tobramycin and 0.5 Ca2+:OPO32- loaded hydrogels disks were submerged in 2 mL 
of 130 mM NaCl, plus 1.5 mM Mg2+, 2.5 mM Ca2+ and 5 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) at pH 7.3 to approximate physiological ionic strength and 
the presence of physiological concentrations of divalent metal ions 46. The 2 mL solutions were 
replaced with fresh 2 mL solutions after 1, 2, 4, 12, and 24 h on day one, then every 24 h 
thereafter. The tobramycin concentration in the solutions was determined using the PRM 
colorimetric assay.  The 2 mL volume was ~15 times greater than the volume of the loaded 
hydrogel (~140 µL) and resulted in tobramycin concentration within the detectable window of 
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the colorimetric assay (0.001 to 0.05 mg mL-1).  
 
4.2.6 Loading and release of vancomycin using 
 UV-Vis spectroscopy 
 Uniform 250 µL hydrogel discs were immersed in 150 mM NaCl and 5 mM Vancomycin 
HCl for 24 h. Vancomycin concentrations were measured by comparing absorbance values at 
280 nm with a standard curve. Total vancomycin loading was measured via depletion of 
vancomycin in the loading solution. Vancomycin release kinetics was performed as described for 
tobramycin in section 2.5. Absorbance measurements were taken from a Spectra Max M2 
cuvette reader.  
 
4.2.7 Mechanical testing of hydrogels 
Hydrogels were compressed while submerged in 130 mM NaCl, 1.5 mM Mg2+, 2.5 mM 
Ca2+, and 5 mM HEPES at pH 7.3 on an Instron 3342 material test system controlled with Bluehill 
3 software (Instron, Inc.). Hydrogels were compressed at a rate of 0.15 s-1 to 80% compression 
for mechanical comparison of loading ratios. For recovery tests hydrogels were cyclically 
compressed to 50% 10 times to maximize hysteresis and modulus reduction. Following the 10th 
cycle the hydrogels were rested while submerged for 30 min and cycled to 50% to determine 
recovery of modulus, hysteresis and strength. In all tests hydrogels underwent an initial 







4.2.8 Compressive cycles and subsequent tobramycin release 
Hydrogels were cyclically compressed to 50% at a rate of 6 cycles per min to assess the 
effect of compression due to manipulation of joints or normal gait on release of tobramycin. 
Hydrogels were immersed in 2 mL of 130 mM NaCl, 1.5 mM Mg2+, 2.5 mM Ca2+ and 5 mM HEPES 
at pH 7.3 during compression with control gels immersed in the same volume under no 
mechanical strain. The solution was replaced every 24 h and concentration of released 
tobramycin was measured with the PRM colorimetric assay.  
 
4.2.9 Infrared spectroscopy 
Ca2+ and tobramycin loaded pPEMA-pAAm hydrogels were lyophilized to remove water, 
and crushed into a powder using an agar mortar and pestle before applying to the diamond ATR 
crystal. ATR-FTIR absorbance spectra were collected using a Nicolet 6700 spectrometer (Thermo 
Scientific, FL) with a diamond Smart iTR accessory, a deuterated triglycine sulfate detector, and 
a KBr/Ge mid-infrared optimized beamsplitter. Spectra were recorded with a resolution of 4 cm-
1 and as 512 averaged scans. The IR spectra were normalized to the intensity of an absorption 
band centered at 1665 cm-1, which corresponds to absorption by amide groups in the 
polymethacrylamide backbone.47 The integrated intensity of bands corresponding to degenerate 
P-O- symmetric stretching modes between 950 and 1050 cm-1 were measured for changes over 
time to identify any loss of phosphates due to hydrolysis.36,48,49  
 
4.2.10 Statistical methods and data processing 
Data are reported as mean +/- 1 standard deviation with an n of 3. Mean and standard 
deviation was calculated using Microsoft Excel. Mechanics data was processed using Matlab 
software (Mathworks). The initial modulus was determined from the slope of a linear fit of the 
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first 15% of the compressive cycle. Strength at 80% represents the maximum stress in the cyclic 
stress strain curve. Energy dissipation, strain cycle hysteresis, was computed by subtracting the 
trapezoidal integration of the reverse curve from the forward curve of cyclical tests. Difference 
between means was tested for statistical significance using a one way ANOVA using IBM SPSS 
Statistical Analysis 24 software.  
 
4.3 Results and discussion 
4.3.1 The utility of a tough, tobramycin loaded hydrogel 
Tough Ca2+ loaded pPEMA-pAAm hydrogels were subsequently loaded with tobramycin 
to act as a prophylactic in orthopedic procedures or to eradicate biofilm based infections arising 
after joint replacement surgery. Tobramycin and gentamycin are the most commonly used 
antibiotics for loading bone cement for orthopedic applications.50 Tobramycin was selected for 
loading into pPEMA-pAAM hydrogels due to its broad spectrum effectiveness against both staph 
and pseudomonas which make up over 80% of orthopedic infections.20,50–53 Vancomycin is a 
common antimicrobial for use in orthopedics, especially against methicillin-resistant S aureus 
(MRSA), and was also explored for loading into pPEMA-pAAM hydrogels but lacked the 
sustained release profile as observed with loaded aminoglycoside antibiotics.54,55  
 
4.3.2 Synthesis of Ca2+ and tobramycin crosslinked double  
network hydrogel 
Crosslinking polycations with phosphates in pPEMA-pAAm hydrogels results in shrinking 
and can be controlled by adjusting the concentration of polycation, which results in sequential 
binding of different fractions of total phosphates. Submerging pPEMA-pAAm hydrogels in Ca2+ 
or polycationic aminoglycoside antibiotics like tobramycin resulted in rapid shrinking of the 
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hydrogel by up to 50% and the emergence of a second network structure comprised of 
electrostatic crosslinks between phosphates and Ca2+ or tobramycin (Figure 4.1C). pPEMA-pAAm 
hydrogels were first loaded with varying ratios of Ca2+ to OPO32- resulting in a controlled volume 
decrease of 50% for higher Ca2+:OPO32- ratios (1.8 and 0.8),  and only 20% volume decrease for 
0.3 Ca2+:OPO32-.  There was no volume decrease when Ca2+ was sufficiently low, 0.1 Ca2+:OPO32- 
(Figure 4.2A,C). The degree of volume change correlates with the amount of available Ca2+ and 
the quantity of formed crosslinks with phosphates. More available Ca2+ and thus more crosslinks 
leads to greater volume change. This volume change was used to estimate quantities of calcium 
required to crosslink only a fraction of phosphate binding sites, thus allowing for a subsequent 
equilibration and crosslinking with positively charged tobramycin.  
To further explore the effect of charge on complex formation and crosslinking, pPEMA-
pAAM hydrogels were loaded with tobramycin at pH ranging from 4 to 9.  Gels shrink to ~50% 
the original volume at pH 4 due to crosslink formation between monovalent phosphates and 
tobramycin with 5 positively charged amines with pKa’s of 6.2, 7.4, 7.4, 7.6 and 8.6, Figure 
4.3A.56 As pH is increased up to 7.7 the hydrogels still shrink by ~50% as phosphates become 
divalent with approximately 2.5 positive charges on tobramycin at pH 7.7.56 At pH 8 the volume 
shrinks by 30% and only by 4% at pH 9, which corresponds to a drop in charge to less than 2+ on 
tobramycin, Figure 4.3A, B. This supports the argument that crosslinking is a result of multiple 
phosphates (that may be monovalent or divalent) interacting with tobramycin, which must have 
at least 2 positive charges to form the complex.  
The combination of a calcium selective probe and colorimetric assay for tobramycin 
provided a quantitative measure of loaded Ca2+ or tobramycin and verified the possibility of 
sequential crosslinking of fractions of unbound phosphates. The total loaded Ca2+ decreased 
from 355 +/- 41, 177 +/- 38, 124 +/- 14, and 47 +/- 11 mg mL-1 with decreasing Ca2+ to OPO32- 
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ratios of 1.8, 0.8, 0.3, 0.1 respectively (Figure 4.2D). The decreasing mass of loaded Ca2+ 
correlated with less shrinking observed with lower amounts of available Ca2+ and is consistent 
with less Ca2+-tobramycin crosslinking. Ca2+ loaded pPEMA-pAAm hydrogels were subsequently 
submerged in 5 mM tobramycin resulting in a volume decrease down to 50% for hydrogels 
loaded with Ca2+ to OPO32- ratios of 0.3 and 0.1 and no volume change for hydrogels already at 
50% volume (Figure 4.2B,C). During tobramycin crosslinking some Ca2+ was exchanged with 
tobramycin in addition to crosslinking the remaining unbound phosphates. The loaded Ca2+ 
decreased during tobramycin loading from ratios of 1.8, 0.8, 0.3 and 0.1 Ca2+:OPO32- to 1.6. 0.5, 
0.2, and 0.1 respectively. Total tobramycin loaded into the hydrogels was determined by 
measuring depletion of tobramycin in the loading solution via a colorimetric assay and was 
greatest at 15 +/- 3 mg mL-1 for hydrogels loaded with the least Ca2+ (0.1 Ca2+ to OPO32-). Loaded 
tobramycin decreased to 72 +/- 2, 164 +/- 3 and 191 +/- 9 mg ml-1 for hydrogels with increasing 
loaded Ca2+; 0.2, 0.5, and 1.6 Ca2+ to OPO32- respectively. This trend of greater tobramycin 
loading with decreasing loaded Ca2+ is illustrated in Figure 4.2D and is explained by there being a 
greater fraction of phosphates available for binding.  
While polyphosphate hydrogels are adept at binding and concentrating aminoglycoside 
antibiotics other antibiotics like glycopeptides such as vancomycin are not retained in the same 
way. For comparison, hydrogels loaded with vancomycin did not result in hydrogel shrinking and 
had a lower loading concentration (1.02 +/- 0.1 mg mL-1) and therefore little or no crosslinking of 
phosphates. Vancomycin has more diverse ionizable groups including one carboxyl, two amino 
and three phenolic and has a total net charge from 2+ to 4-, depending on pH.57 At pH 7.7, the 
net charge falls between 0 and 1-, which may explain the lack of electrostatically driven 
crosslinking of negatively charged phosphates.57 In addition to charge differences, glycopeptides 
have much larger molecular weights than aminoglycosides; 1449.3 g mol-1 for vancomycin 
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versus 467.5 g mol-1 for tobramycin. Furthermore, glycopeptides have cyclical structures with 
carbohydrate and peptide components, which could affect the charge distributions or densities 
and therefore binding with phosphates in the hydrogel.   
 
4.3.3 Metal-phosphate crosslinks increase modulus and strength 
The formation of Ca2+-phosphate crosslinks has been shown to significantly increase the 
modulus and toughness of pPEMA-pAAm hydrogels, which is dependent upon the quantity of 
available Ca2+ and thus number of added crosslinks. Caddisfly silk derives toughness from serial 
regions of Ca2+-phosphate domains that viscously unravel upon strain followed by self-recovery 
of ruptured Ca2+-phosphate bonds as directed by an elastic recoiling force. The inclusion of a 
sacrificial, self-recovering domain in combination with a permanent elastic network and high 
water content classify the caddisfly silk as a naturally occurring double network hydrogel 
material. This natural toughening mechanism has been replicated in the double network 
pPEMA-pAAm hydrogels with similar Ca2+-phosphate domains coinciding with a covalently 
crosslinked elastic pAAm network. The initial modulus of the Ca2+ loaded hydrogels was highest 
at 0.8 +/- 0.07 MPa with the highest amount of loaded Ca2+ at 1.8 mol Ca2+:OPO32-. As the molar 
ratio of loaded Ca2+ to phosphate decreased from 1.8 to 0.1 the modulus decreased from 0.8 +/- 
0.07 MPa to 0.01 +/- 0.001 MPa, corresponding to decreased Ca2+-phosphate crosslinks (Figure 
4.3C).  The strength at 80% compression was 2.9 +/- 0.6, 2.6 +/- 0.7, 0.07 +/- 0.003, 0.05 +/- 
0.001 MPa for Ca2+:OPO32- ratios of 1.8, 0.8, 0.3, 0.1 respectively (Figure 4.3F). 
Like volume decrease, change in hydrogel initial modulus can also be used as a rough 
indication of quantity of crosslink formation. While a decrease in volume and increase in 
modulus indicate crosslink formation, the volume change and initial modulus do not correlate in 
exactly the same way. Volume was minimized around ~50% with only 0.8 Ca2+ per OPO32-, 
69 
 
however the initial modulus continued to increase with increasing Ca2+ up to 1.6 Ca2+ per OPO32-. 
This may suggest there is some fraction of phosphates required for complete volume decrease 
upon crosslinking, which is less than the total number of possible crosslinks as evidenced by 
increased modulus and strength with increasing calcium after volume has reached steady state. 
Alternatively, there may be an optimization process where increased Ca2+ promotes reformation 
of transient Ca2+-phosphate bonds leading to more stable complexes. 
 
4.3.4 The effect of tobramycin crosslink formation on  
hydrogel mechanics 
Inclusion of tobramycin crosslinks into Ca2+ loaded pPEMA-pAAm hydrogels reduces 
toughness by reducing the initial number of possible Ca2+ crosslinks and through an exchange 
process where some existing Ca2+ bonds are replaced by weaker tobramycin crosslinks. For 
hydrogels with a ratio of 1.8 and 0.8 Ca2+:OPO32-, the addition of tobramycin and corresponding 
reduction in Ca2+ OPO32- crosslinks led to a decreased modulus from 0.8 +/- 0.07 to 0.7 +/- 0.2 
MPa and 0.6 +/- 0.1 to 0.2 +/- 0.1 MPa, respectively (Figure 4.4A-E). Additionally there was a 
change in strength at 80% compression from 2.9 +/- 0.6 to 3.0 +/- 0.2 and 2.6 +/- 0.7 to 1.8 +/- 
0.05 MPa respectively (Figure 4.4A,B,D-F). Previously the strength of metal-phosphate crosslinks 
was shown to be dependent on metal species identity; driven by changes in charge density, 
atomic radii, and coordination geometry between metals and phosphates where metals like Ca2+ 
were suspected of binding in an inner sphere mode and metals like Mg2+ with a high affinity for 
an inner sphere hydration shell bind phosphates in an outer sphere mode.41 Tobramycin at 468 
g/mol is >> than Ca2+ at 40 g/mol and results in a decrease in charge density resulting from the 
greater molecule size. Additionally the increased molecular size may result in less efficient 
crosslinking with less phosphates complexed compared to metals. Consequently, tobramycin 
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crosslinked hydrogels are weaker than Ca2+ crosslinked hydrogels as evidenced by the decrease 
in initial modulus and strength.  
When the initial amount of loaded Ca2+ drops below 0.5 Ca2+:OPO32- tobramycin 
crosslink formation has a marginal toughening effect compared to unloaded pPEMA-pAAm 
hydrogels and resists fracture. For hydrogels loaded at lower ratios of 0.3 and 0.1 Ca2+:OPO32-, 
the addition of tobramycin results in an increased modulus from 0.03 +/- 0.01, and 0.01 +/- 
0.001 to 0.09 +/- 0.02 and 0.04 +/- 0.01 MPa respectively (Figure 4.4C). This is a result of 
minimal Ca2+ crosslinking initially, thus the final mechanics of these hydrogels is driven by 
tobramycin crosslink formation instead of Ca2+. In both cases (more Ca2+ crosslinks or more 
tobramycin crosslinks) the emergence of a double network structure comprising both 
electrostatic bonds and covalent crosslinks increases hydrogel toughness. Both Ca2+ and Ca2+-
tobramycin hydrogels resist fracture and do not fail when compressed to 80%. In contrast, 
primarily single network hydrogels with low calcium, 0.1 Ca2+:OPO32-, and no tobramycin fail 
prior to 80% compression (Figure 4.4E, blue curve).  
 
4.3.5 Reversible phosphate crosslinks lead to recovery of 
 modulus and hysteresis 
 Natural caddisfly silk strained in tension recovered close to 100% hysteresis area or 
energy dissipating potential after 120 m. The recovery behavior has been linked to rupture and 
reformation of electrostatic bonds between phosphate and divalent metal ions, which allow for 
beta-sheet protein structure to unravel and reform over multiple strain cycles. Double network 
pPEMA-pAAm hydrogels crosslinked with Ca2+ and tobramycin exhibit a recoverable reduction of 
modulus, energy dissipation, and strength at 80% compression over multiple compressive cycles 
(Figure 4.5A). The reduction in modulus, energy dissipation, and strength is 0.2 +/- 0.02, 0.1 +/- 
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0.01 and 0.6 +/- 0.02 MPa respectively between the 1st and 10th cycles. This is recovered by 113 
+/- 10%, 108 +/- 7%, and 93 +/- 3% respectively over a 30 min dwell time (Figure 4.5B). The 
mechanical recovery mirrors observations from caddisfly silk and can be attributed to the 
transient nature of the Ca2+ or tobramycin OPO32- crosslinks. In natural systems, like caddisfly 
silk, phosphate-Ca2+ complexes play a mechanical role and recoverability was linked to the 
reversible nature of the phosphate-metal complexes, which rupture upon strain and then 
spontaneously recover. Additionally, prior work with pPEMA-pAAm hydrogels loaded with Ca2+ 
demonstrated pseudo-yield behavior in tension as crosslinks were ruptured at a critical stress 
and reformed following strain as directed by an elastic restoring force.  The hysteresis, shown in 
Figure 4.5A, is evidence of rupture of phosphate-Ca2+ bonds and associated energy dissipation. 
Progressive loss of hysteresis across multiple strains can be attributed to accumulating ruptured 
complexes with insufficient time for complete recovery between cycles. When the cycle dwell 
time is increased to 30 m, Figure 4.5B, recovery is near 100%. This shows that the recovery 
behavior of pPEMA-pAAM hydrogels is similar in compression compared to tests in tension and 
is dependent upon a transient crosslinked network of phosphate-metal complexes.  
 
4.3.6 Sustained elution of tobramycin and vancomycin from tough 
 double network hydrogels 
Interactions between phosphates and tobramycin led to retention and sustained release 
of tobramycin for up to 66 days, Figure 4.6A. The tobramycin release rates were determined in a 
saline with Mg2+ and Ca2+ ions, the most abundant multivalent metal ions in blood and serum.46 
Ca2+ and tobramycin loaded pPEMA-pAAm hydrogel disks (250 µL volume) were incubated in 2 
ml solutions of 130 mM NaCl plus 2.5 and 1.5 mM Ca2+ and Mg2+, respectively, at pH 7.3. The 
solutions were replaced every 24 h and the tobramycin concentration in the solution was 
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determined using a colorimetric assay for primary amines.  The pPEMA-pAAm hydrogels 
released 59 +/- 8.7 µg of tobramycin in the first 24 h (Figure 4.5B). The initial burst was likely 
due passive diffusion of unbound tobramycin entrapped in the hydrogel matrix. During the next 
24 h, the rate of tobramycin release declined to 27.9 +/- 4.8 µg and then declined gradually to 
0.1 +/- 0.5 µg mL-1 over 66 days (Figure 4.5B). The cumulative tobramycin release after 66 days 
was 1089 +/- 67 µg (Figure 4.5A). The sustained tobramycin release from the pPEMA-pAAm 
hydrogels has been speculated to be due to restricted diffusion of tobramycin, due to reversible 
electrostatic interactions with phosphate sidechains, or restricted diffusion due to hydrogel 
shrinkage, which resulted in decreased porosity of the hydrogel network. Furthermore, slow 
hydrolysis of the two ester linkages in the phosphate sidechains, and thus a degradation driven 
release, was not seen as a major contributor because the integrated intensity of ATR-FTIR 
spectra corresponding to the P-O- vibrational modes remained unchanged over 66 days, Figure 
4.7. Additionally, the compressive modulus was 0.19 +/- 0.1 MPa after 8 weeks which was not 
statistically different (P>0.9) from hydrogels at week 1 (0.2 +/- 0.1 MPa) suggesting a constant 
quantity of phosphate-calcium crosslinks.  
Total cumulative tobramycin release after 66 days was ~ 12% of the total tobramycin 
loaded into the hydrogels. Similarly low percentages of total release have been observed in 
other ionic systems. For example, a viscous gel of poly(allylamine hydrochloride) and inorganic 
polyphosphate released less than 3% of a charged drug proxy over 160 days.21 In comparison, 
when pPEMA-pAAm hydrogels were previously loaded with only tobramycin the release of total 
drug was 5%. The difference in total drug released is not explained by tobramycin loading; 0.5 
Ca2+:OPO32- tobramycin crosslinked hydrogels had lower total loaded drug 70 mg mL-1 versus 200 
mg mL-1 in the tobramycin only loaded hydrogels. Additionally the total amounts of released 
tobramycin were similar, 1.089 mg for Ca2+-tobramycin loaded hydrogels versus 0.75-1.25 mg 
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for tobramycin only loaded hydrogels, despite the difference in total loaded drug. This could be 
explained if tobramycin is released primarily from the surface resulting from accumulative 
electrostatic resistance to diffusion that may increase with hydrogel depth. By loading hydrogels 
in Ca2+ and inducing volume change before loading with tobramycin there may be an associated 
decrease in tobramycin loading in the center of the hydrogel but maintaining the total drug 
released from the surface.  
In contrast to tobramycin loaded hydrogels, vancomycin loaded hydrogels did not 
exhibit the same prolonged release profile and are only usable in applications that would 
require a short vancomycin regimen of up to 5 days. The pPEMA-pAAm hydrogels released 560 
+/- 11.1 µg of vancomycin in the first 24 h (Figure 4.6B). The daily release of vancomycin 
decreased to 0.2 +/- 0.2 µg ml-1 over 5 days (Figure 4.6B) with a cumulative vancomycin release 
of 730 +/- 17 µg. In comparison, a pAAm hydrogel loaded with tobramycin released 100% of its 
payload within 48 h.4 In this case, an absence of phosphates in the hydrogel led to passive 
diffusion of the entire drug payload. While vancomycin has no net positive charge at pH 7.3 the 
release rate is twofold greater than diffusion of tobramycin from a pAAm hydrogel. It is possible 
that there are localized positive charges related to the two primary amine groups in the 
vancomycin structure, which interact with phosphates but are insufficient to extend release 
beyond 5 days. The increased size of vancomycin may also contribute to differences in charge 
distribution or density which may prevent crosslinking. Furthermore, vancomycin loaded 
hydrogels released 70% of the payload within 5 days illustrating some minimal level of 
electrostatic retention but not enough to produce dramatic hydrogel shrinking and retention of 
the drug.  
A concern with antibiotic eluting materials and devices is that the antibiotic 
concentration could fall below the bactericidal concentration before the infection is completely 
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eradicated, creating an environment for selection of antibiotic resistance strains. While the in 
vitro elution conditions may not perfectly reflect in vivo conditions in tissues, the continuous 
release above 2 ug mL-1 for 60 days is greater than a previously determined bactericidal 
concentration for tobramycin against P.aeruginosa.4 This prolonged elution as well as the large 
cumulative amount of tobramycin released, suggested the pPEMA-pAAm hydrogels can be 
capable of complete eradication of established infections in vivo before the release rate tails off, 
and therefore will have low potential for promoting development of bacterial drug resistance. 
 
4.3.7 The effect of compression on tobramycin elution 
Where pPEMA-pAAm hydrogels may be used as structural materials in joints 
compressive strains can effect the release behavior of tobramycin. Tobramycin loaded hydrogels 
were compressed to 50% at a rate of 6 cycles per min for 24 h increments. Over the first 24 h, 
tobramycin release increased from 59 +/- 8.7 ug mL-1 to 88.7 +/- 6.1 µg mL-1 with the addition of 
compressive cycles, Figure 4.8. Under cyclic compressive strain, tobramycin release through 
days 2-4 was increased by 6, 10, and 5 µg per day, Figure 4.8. Compressive strain could increase 
tobramycin release in multiple ways. One, strain induced rupture of phosphate tobramycin 
crosslinks could result in an increase of the population of tobramycin bound to only a single 
phosphate and thus rise the rate at which tobramycin diffuses out of the hydrogel. Two, 
compressive cycles force additional fluid flow both in and out of the hydrogel structure which 
can result in transportation of tobramycin due to the introduction of a flow rate which is faster 
than passive diffusion. While compressive cycles led to an increase in daily tobramycin release 
the increase was not great enough to deplete the loaded tobramycin reserve in a way that 





The polyphosphate hydrogels used a network dense in phosphates as a dual mechanism 
for toughening with Ca2+ crosslinks and sustaining tobramycin release for over 60 days via 
electrostatically reduced diffusion rates and could be useful as orthopedic materials for both 
fighting infection and structural components. In orthopedic applications antibiotics are chosen 
to have broad spectrum effectiveness and limited resistant strains. Tobramycin and gentamycin 
are the most commonly used gram negative antibiotics and vancomycin for gram positive.58 
Orthopedic materials often include calcium-phosphate matrices such as hydroxyapatite,54 
biphasic calcium phosphate59,60 and calcium polyphosphate powders54 paired with vancomycin 
to create bone replacement materials while fighting infection. In these cases the calcium-
phosphate matrix are ceramic or dense putty and release of antibiotic is driven by diffusion and 
degradation of the matrix with sustained release for only a few days. Bone fillers and antibiotic 
impregnated bone cements have also been deployed as a preventative measures in joint 
replacement. An inorganic bone filler ProOsteon 500R has been mixed with polycaprolactone, 
polyethylene glycol, poly(D,L-lactide-co-glycolide), and tobramycin to form a moldable 
composite bone void filler with sustained release of tobramycin for over 20 days.61 Gentamycin 
and tobramycin loaded cements like Palacos-R or Simplex-P have been formed into spacers via 
injection molding for use as a high dose prophylaxis during joint replacement and were 
demonstrated to release for up to 1 week.62 Simplex-P cement loaded with tobramycin was 
shown to be effective against 99 strains representative of orthopedic infection including both 
gram positive, gram negative and strains resistant to systemic levels of tobramycin.63 Previously, 
similar polyphosphate hydrogels loaded with only tobramycin were shown to totally eradicate 
P.aeruginosa biofilms in vitro within 72 h and were capable to maintaining zones of inhibition 
against P.aeruginosa for 4 weeks.4 While polyphosphate hydrogels are probably not realistic 
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complete replacements for bone substitute materials that are replaced over time by natural 
bone, they could be included as a bone patch or mixed in as particles to extend the release of 
tobramycin.  
A more obvious application for tough, tobramycin releasing polyphosphate hydrogels is 
as a spacer or artificial cartilage layer in total joint replacement surgery. In addition to localized 
sustained antibiotic elution the reported hydrogels mechanically demonstrated potential as 
structural components in joint replacement. Articular knee cartilage acts as a load distributer 
with normal loads ranging between 1-3 body weights depending on gait and cartilage location, 
proximal or distal and medial or lateral.64,65 Loads were normalized by dividing by the average 
normal knee contact surface area.66 As a result, cartilage or meniscus replacement materials 
should be capable of distributing forces of 1-2 MPa, this is in agreement with a similar published 
benchmark by J.P. Gong.67 pPEMA-pAAm hydrogels loaded with Ca2+ and tobramycin were 
capable to withstanding several MPa loads by 80% compression without failure. The modulus of 
articular cartilage ranges from 6 to 14 MPa,68,69 while the reported 0.5 Ca2+:OPO2- hydrogel had a 
modulus of 0.2 MPa. Previous work showed an increase in modulus for pPEMA-pAAm hydrogels 
from 10 MPa to 34 MPa by replacing Ca2+ with Zn2+, which could be explored in future work.41 
Aditionally, the loading and release mechanism is unique, as mechanical manipulation of the 
material can alter the release behavior and expand the possible uses of pPEMA-pAAM hydrogels 




Figure 4.1: Schematic diagram of the synthesis and loading of pPEMA-pAAm tobramycin double 
network hydrogels: A) Structure of pPEMA-MA, acrylamide and bis-acrylamide. B) Double 
network structure after copolymerization of pPEMA and pAAm. C) Collapse of the 
polyphosphate network and expulsion of water due to electrostatic crosslinking of phosphates 







Figure 4.2: Loading of Ca2+ and tobramycin and associated volume change. A) Normalized 
volume change with addition of Ca2+ at ratios of 1.8 (Purple), 0.8 (black), 0.3 (green) and 0.1 
(blue) Ca2+ to OPO32-. B) Post Ca2+ addition of tobramycin results in further volume change and 
final Ca2+ to OPO32- ratios of 1.6 (purple), 0.5 (black), 0.2 (green) and 0.1 (blue). C) Final 
normalized volumes with Ca2+ (blue) and after tobramycin loading (red). D) Total loaded cation 







Figure 4.3: Normalized hydrogel volume reduction resulting from tobramycin loading A) 
Normalized gel volume reduction resulting from tobramycin loading is dependent upon pH. B) 
pH changes affect total charge on tobramycin (x axis) and charge on phosphate (red = less than -







Figure 4.4: Representative stress strain curves for pPEMA-pAAm hydrogels with Ca2+ (blue) and 
after tobramycin loading (red). A) Final ratio of 1.6 Ca2+:OPO32-. B) Final ratio of 0.5. D) Final ratio 
of 0.2. E) Final ratio of 1.6. C) Comparison of initial modulus for hydrogels loaded with Ca2+ 
(blue) and after tobramycin loading (red) for all final ratios of Ca2+:OPO32-. F) Strength at 80% 
compression for hydrogels loaded with Ca2+ (blue) and after tobramycin loading (red). Error bars 







Figure 4.5: Recovery of mechanics following multiple cyclical compressive strains. A) 
Representative series of 10 compressive cycles of a pPEMA-pAAM hydrogeld loaded with 0.5 
Ca2+:OPO32- and tobramycin. B) Representative stress strain curves showing the 2nd compressive 
cycle (black) excluding the first cycle as a conditioning step, and 10th cycle (blue) and subsequent 
cycle following a 30 min dwell time (red). Recovery of modulus, hysteresis, and strength is 






Figure 4.6: Controlled release of vancomycin or tobramycin from pPEMA-pAAm hydrogels 
loaded with 0.5 Ca2+:OPO32-. A) Cumulative release of tobramycin (black) and vancomycin (red). 









Figure 4.7: Normalized ATR-FTIR spectra in the region corresponding to P–O- vibrational modes 
of Ca2+ and Tobramycin equilibrated pPEMA-pAAm hydrogels. The initial spectra for hydrogels is 
shown in red and then the spectra is retaken after 65 days in 130 mM NaCl, 2.5 mM Ca2+, and 
1.5 mM Mg2+ at pH 7.3. Spectra curves are representative and there was no statistical 







Figure 4.8: Effect of compression on tobramycin release A) Cumulative release of tobramycin 
from pPEMA-pAAm hydrogels B) Daily release of tobramycin from pPEMA-pAAm hydrogels. 
Hydrogels under cyclic compression are shown in black and control hydrogels with under zero 
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EMULSION OF POLYPHOSPHATE- TOBRAMYCIN COMPLEX COACERVATES FOR 
PULMONARY DELIVERY OF AMINOGLYCOSIDES TO TREAT CHRONIC  




5.1.1 Cystic fibrosis leads to chronic pulmonary infection 
 
Cystic Fibrosis (CF) is a life shortening genetic disease with significant adverse effects to 
the lungs including irregular mucus secretions and increased risk for infection.1 Mutation occurs 
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene leading to abnormal 
CFTR protein. This abnormality results in ineffective ion transport across epithelial mucosal cells 
leading to salt and water imbalance and consequently more viscous sticky mucus excretions.2–5 
Associated complications include: liver disease, pancreatic insufficiency, diabetes, and chronic 
lung infection, the leading cause of CF related death.1,6,7  
The effect on the lungs is profound and disrupts normal lung immune response. The 
principal cause of reduced pulmonary immune response is complex and derives from multiple 
sources. Because mucus cannot be easily cleared from the airways, it provides an ideal niche for 
invasion of opportunistic bacteria. There is a link between the lack of CFTR protein and 
associated decrease in secretion of HCO3-, which in the presence of continued proton release 
results in lower pH or acidification of the surface airway liquid.8 This acidification has been 
92 
 
suggested as an critical factor for explaining reduced effectiveness of the host immune system.8 
The combination of lack of mucosal clearance, surface airway acidification and formation of 
biofilms illustrates the complex environment that has resulted in chronic airway infection in 
cystic fibrosis. 
Most CF patients experience some form of acute infection with gram-negative 
Pseudomonas aeruginosa  most  common.  These  initial  infections  eventually  progresses  into  
chronic  biofilm  based infection in almost all cases.9 Despite extensive research and clinical 
efforts to eradicate chronic infection in CF patients, there is currently no successful solution for 
eradicating chronic P. aeruginosa infection.9–11  
 
5.1.2 Biofilms reduce the effectiveness of current chemotherapies 
 
Biofilms are an exopolysaccharide matrix secreted by adhered bacterial cells that 
increases antibiotic resistance by up to 1000 fold.12–14 The complex biofilm structure includes 
large plumes and channels, hypothesized to transport nutrients throughout the biofilm and 
potentially transporting antimicrobials away, both of which improve surviability.15 Furthermore, 
even after successful infection eradication these complex biofilm structures may be vacant but 
still intact, thus facilitating an external reseeding event by new pathogen invaders. This could be 
a potential explanation for why acute infection in younger CF patients eventually transitions into 
chronic infection.  
Increased resistance could result from frustrated penetration of antibiotics into the 
biofilm. In the case of positively charged aminoglycosides, absorption to negatively charged 
biofilm components may reduce drug effectiveness.16,17 Frustrated diffusion of aminoglycosides 
may be a short term problem because eventually all binding sites would be occupied and lead to 
a restoration of diffusion. As a contrasting view, some authors have argued that slowed 
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diffusion may accentuate an enzymatic inactivation of the antibiotics.12,13 
While the 3-dimensional biofilm structure and potential reduction in diffusion are 
factors in antibiotic resistance they do not explain why even after eventual saturation of the 
biofilm with antibiotics there is ineffective eradication of bacterial cells.  Multiple researchers 
have revealed a significant nutrient and oxygen gradient across the biofilm.18,19 Oxygen levels 
and protein synthesis are directly linked to metabolic activity in the bacterial cells with only 
metabolically active cells having normal antibiotic suceptiability.20,21 Near the biofilm surface 
bacteria remain in an aerobic metabolic state and are readily killed with chemotherapy. In 
contrast, bacteria in the interior transition to an anaerobic metabolic state with far less 
susceptibility to aminoglycoside antibiotics.18,19 
Along with nutrient driven metabolic changes, biofilm structures, and frustrated 
antibiotic diffusion it is known that some subset of the population (~1%) will experience a 
phenotypic change resulting in tolerance to antibiotics. Called “persister” cells, these bacterial 
cells repopulate the colony following what would have been eradication events such as 
exposure to antibiotic treatment.22 Treating biofilm infections becomes more complex over 
time. Long term infections, like those observed in chronic pulmonary infection in cystic fibrosis 
become more difficult to combat as the infection matures. There are genetic adaptations in 
chronic infection over several years that leads to a loss of virulence factors.9 While virulence 
factors are important for initial invasion, it has been suggested that these factors are also 
ligands for the human immune system and the subsequent loss may yield a more robust 
bacterial population.9 In addition, these mutations may represent a symbiotic step in preserving 
the host organism as well as a decreased need to injure the host to generate nutrients. The 




5.1.3 Current treatments and patient compliance 
 
State of the art care guidelines for P. aeruginosa infection includes inhaled Tobramycin 
(aminoglycoside) for 28 day cycles.23 Tobramycin works via accumulation on the bacterial cell 
surface, prompting an energy dependent uptake into the cell. Subsequent binding of tobramycin 
to RNA prevents protein synthesis, resulting in cell death.24 Treatment with tobramycin has 
shown success in early acute P.aeruginosa infection, but is ineffective in terms of total 
eradication of chronic infection. Additionally, the burden of taking multiple doses per day for 28 
day cycles including the time to nebulize the drug and sanitize the equipment after every dose 
leads to decreased patient compliance. This is further exacerbated by additional time intensive 
tangential therapies including physical therapy and pharmaceutical treatments for inflammation 
of airways, mucolytics, digestion, diabetes, and liver disease. While these metrics are difficult to 
measure the compliance rates for some treatments is estimated to be as low as 16-20%.25–28 
pPEMA–tobramycin coacervates can be used to prolong delivery of tobramycin and could 
decrease the number of daily treatments thus easing the burdens that decrease patient 
compliance. Additionally, tobramycin coacervates could improve tobramycin effectiveness 
against Aeruginosa biofilms by maintaining a constant concentration of tobramycin and by 
sequestering metal ions, which have been linked to the biofilm structure and inflammation, in 
an exchange process with tobramycin.  
 
5.1.4 Complex coacervates: formation and physiochemical  
properties 
 
It is proposed that a complex coacervate of poly-anionic polyphosphate and poly-
cationic tobramycin can be aerosolized and delivered to the lungs, resulting in sustained release 
of tobramycin. Coacervation was first identified by F.W. Tiebackx in 1911 as a liquid-liquid phase 
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separation in a colloidal system. 29–31  A coacervate is comprised of a dense “coacervate” phase 
and a dilute “equilibrium” phase. A theoretical explanation of coacervation began in 1957 by 
J.Overbeek and M. Voon, which described coacervation both electrostatically and through 
entropy. 32 Coacervation is driven by attractive forces between oppositely charged particles and 
an entropic driving force from delocalization of counter ions from cationic and anionic 
components to form a neutral “complex”.31 When both polyions are oppositely charged 
polymers the process has been coined complex coacervation. Several physiochemical conditions  
have been identified that effect coacervate formation including: polyelecrolyte strength, mixing 
ratio and charge balancing, salt concentration, polymer mobility and temperature.31 It was 
predicted that strong polyelectrolytes may form precipitates rather than liquid coacervate, 
charge balancing leads to maximum coacervate yield, and salt will have a dissociating effect on 
complex formation at both high and low concentrations.31 By mixing negatively charged pPEMA 
with positively charged tobramycin in an aqueous solution of 1 M NaCl, tobramycin coacervates 
can be formed and then aerosolized for deposition in the airways.  
 




Phosphorus(V) oxychloride, 2-hydroxyethyl methacrylate, triethylamine, and glycidyl 
methacrylate were purchased from Alfa Aesar (Ward Hill, MA). Methacrylic acid, 2,2’-azobis(2-
methylpropionitrile), acrylamide, N,N’-methylene-bisacrylamide, and N,N,N’,N’-
tetramethylethylenediamine were purchased from Sigma Aldrich (St Louis, MO). Ammonium 
persulfate was purchased from Fischer Scientific (Pittsburgh, PA). Tobramycin (97%) was 




5.2.2 Synthesis of MOEP monomer and polyPEMA-MA copolymers 
 
2-(Methacryloyloxy)ethyl phosphate (MOEP) was synthesized as previously described.33 
Briefly, phosphorus oxychloride (33.9 g, 220 mmol) and hydroxylethyl-methacrylamide (HEMA) 
were mixed at a 0.7:1 molar ratio in dry toluene (480 mL) under argon. The reaction was stirred 
at 4° C and triethylamine (TEA) (77 mL) added in three increments over 10 m. The reaction was 
stirred at 21-23° C for 6 h under argon, then filtered to remove precipitated trimethylamine 
hydrochloride salt . The reaction was cooled to 4° C before the addition of deionized water (480 
mL), then stirred under argon at 22° C for 12 h. The reaction was extracted twice with diethyl 
ether (100 mL) and the organic layers discarded. MOEP was extracted from the aqueous layer 
into tetrahydrofuran (THF) and diethyl ether (1:2, 12 X 225 mL), then dried over anhydrous 
sodium sulfate before evaporating the solvent. A pale yellow, oil product (MOEP) was produced 
with an approximate 60% yield. Monomer structure was verified through H1 and P31 NMR.  
Poly(phosphoethyl-methacrylate-co-acrylic acid) (pPEMA-AA) was synthesized by free 
radical polymerization of MOEP (85 mol%), and methacrylic acid (15 mol%) in methanol (12.5 mL 
mg-1 MOEP).  MOEP and methacrylic acid were degassed by bubbling with argon for 1 h, 
followed by addition of azo-bis-isobutyronitrile (AIBN, 4.5 mol%) at 55°C to initiate 
polymerization. The reaction was stirred for 15 h before precipitation with acetone, then 
dissolved in water (200 mL H2O per 17 g pPEMA-AA). Afterward, methacrylate groups (MA) were 
grafted onto the methacrylic acid sidechains by adding glycidyl methacrylate to the aqueous 
solution in 9-fold molar excess relative to the carboxylate sidechains and stirred at 21-23° C for 
12 h. The methacrylated pPEMA-AA (pPEMA-MA) was adjusted to pH 7.3 with NaOH and 
purified by tangential flow filtration using a Millipore Pellicon 3 cassette filter with an Ultracel 10 
kD membrane. The polymer product was lyophilized, and stored at -20°C. To produce a 
fluorescently labeled pPEMA-MA, fluorescein o-acrylate was added during polymerization at a 
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molar ratio of 1 fluorescein to 100 MOEP. 
The structure and composition of the monomer (MOEP) and polymers (pPEMA-MA) 
were verified by 1H and 31P NMR.34 The pPEMA-MA polymer contained 65 mol% phosphate 
sidechains, 12 mol% HEMA, and 23 mol% MA sidechains. The molecular weight (Mw) and 
polydispersity index (PDI) of pPEMA-MA were determined by size exclusion chromatography 
(SEC) on an Agilent Infinity 1260 HPLC system with a PL-Aquagel-OH Mixed-M column (8 µm, 
300x 7.5 mm) column. The column buffer was 0.1 M NaNO3 / 0.01 M NaH2PO4, pH 8.0 with a 
flow rate of 1 mL m-1. The average Mm and PDI, 46 kg mol-1 and 1.67, respectively, were 
estimated using sodium polymethacrylic acid standards.  
MOEP;  1H NMR (D2O, 400 MHz); 5.9 (s, 1H), 5.5 (s, 1H), 4.2 (m, 2H), 4.0 (m, 2H), 1.7 (s, 3H).  
  31P NMR (D2O, 400 MHz), 0.213 (s).  
pPEMA-MA; 1H NMR (D2O, 400 MHz); 6.1 (s, 1H), 5.6 (s, 1H), 4.2 (m, 2H), 4.1 (m, 2H), 3.5 (m, 
2H), 1.8 (t, 2H), 1.0 (s, 3H), 0.8 (s, 3H). 
 
5.2.3 Determination of effects of salt and temperature on yield and form  
of pPEMA-MA and tobramycin complex coacervates 
 Complex coacervates were formed by dissolving pPEMA-MA and tobramycin in aqeous 
NaCl (0-1.5 M) at a 1:1 charge ratio,pH 7.4 and 5° to 40° C. Solutions comprised 25 mg mL-1 of 
both pPEMA-MA and tobramycin for a  total concentration of ~50 mg mL-1, Figure 5.1. 
Coacervate formation was assumed to be complete with the formation two liquid phases and 
when the dilute phase changed from cloudy to clear which indicated coalescence of coacervate 
droplets into a single, fluid coacervate phase, Figure 5.2. The mid-point of pPEMA-MA 
phosphate transition from mono- to dianionic has been previously estimated at pH 7.4 and the 
total charges on tobramycin have been estimated at ~2.8 at pH 7.5, which leads to a 1:1 charge 
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ratio with equal mass of polymer and tobramycin.34,35 The effects of salt during coacervation on 
yield and form were determined by varying NaCl concentration from 0 to 1.5 M. The effect of 
temperature was determined using a MJ Research PTC-150 Mini Cycler to vary the temperature 
between 5° and 40° C. Single coacervate samples were used over a variety of temperatures but 
the order of temperature points was randomized. Yield was optically measured by 
photographing coacevates in PCR 250 µL tubes and comparing to a standard curve derived from 
photographs of PCR tubes with known volumes. After 24 h coacervates were classified as cloudy 
or clear or as a gel if there was no flow after tilting the tubes at 90 degrees for one min, Figure 
5.3 D-F. Coacervates for subsequent experiments were formed in 1 M NaCl at ~22° C.  
 
5.2.4  Determining tobramycin concentration in both dense  
and dilute phases 
 Tobramycin concentration in the coacervate was determined by measuring depletion of 
tobramycin from the dilute phase after coacervation was assumed to be complete. Tobramycin 
concentrations were measured colorimetrically using a Pyrogallol Red-Molybdate (PRM) assay 
for primary amines 36–38. A PRM solution was prepared by mixing 0.4 mL of 1.2 mg/mL pyrogallol 
red in methanol, 9 mL of a solution of 55 mM succinic acid and 4 mM sodium benzoate, and 0.04 
mL each of 12 mM disodium molybdate and 261 mM sodium oxalate. Tobramycin containing 
samples (40 µL) were added to 160 µL of the PRM solution in a clear 96 well plate. After 30 m at 







5.2.5  Resuspension of coacervate emulsion and analysis of aerosolized 
 mass and droplet size 
 Clear, fluid coacervates were hand shaken for 1 m to re-suspend the coacervate into a 
cloudy solution of micro-coacervate droplets. Droplet size was estimated by taking DIC images 
from emulsion droplets placed on microscope slides immediately following resuspension by 
vortex. Using Image J, DIC images were converted to 8-bit images then a common threshold was 
applied and particle size calculated using the Image J analyze particles function. The 
resuspended solution or coacervate emulsion was aerosolized using a Respironics nebulizer 
attached to an Inspiration Elite compressor. Mass of aerosolized coacervate was estimated by 
aerosolizing coacervate emulsion onto pre-weighed tissue paper for 2 m. Subsequently, the 
tissue paper was dried via evaporation at 22° C for 15 m. Dry tissue paper was weighed and the 
mass of aerosolized materials between coacervate, free tobramycin and saline was compared. 
Additionally, an aerosolized mist of tobramycin coacervate was collected onto round glass cover 
slips for between 4-5 s and immediately placed into 2 mL of 130 mM NaCl, 1.5 mM Mg2+ and 
2.5 mM Ca2+ at pH 7.3. After 24 h concentration of aerosolized tobramycin was quantified using 
the colorimetric PRM assay. Finally, fluorescently labeled pPEMA-MA was used in tobramycin 
coacervate formation and aerosolized onto standard glass slides and fluorescently imaged. 
Rapid formation of salt crystals prevented estimation of aerosolized droplet size via fluorescent 
microscopy but coacervate thin film formation was verified by measuring integrated intensity of 
the image using Image J and compared to the integrated intensity of an aerosolized 1 M NaCl 
saline.  





5.2.6 In vitro release kinetics of tobramycin from tobramycin 
phosphate coacervate 
Polyphosphate-tobramycin coacervates were formed in 2 mL aliquots in glass vials to 
form a thin coacervate layer on the bottom of the vial. The thickness of the coacervate layer was 
calculated by using the known surface area of the glass vial and know coacervate volume yield. 
The coacervate layer from a single 2 mL aliquot was approximately 0.3 mm thick. After 
coacervate formation the dilute phase was replaced by new 2 mL aliquots to produce 
coacervate layers of 0.6 and 1.2 mm thickness. After coacervate formation the dilute phase was 
replaced by 150 mM NaCl or a solution containing biologically relevant metals, 1.5 mM Mg2+ and 
2.5 mM Ca2+, then replaced again every 24 h and measured for tobramycin concentration using 
the PRM colorimetric assay.  
 
5.2.7 Assessing the effectiveness at polyphosphate-tobramycin coacervate  
against gram negative bacteria in cystic fibrosis sputum  
and CFU quantification 
 
 Cystic fibrosis sputum was collected from patients from the Adult Cystic Fibrosis Center 
at the University Hospital, Salt Lake City, Utah. The study was reviewed and approved by the 
University of Utah Investigational Review Board (IRB). Written, informed consent was obtained 
from patient volunteers prior to collecting samples and data. Patients who presented with 
chronic P.aeruginosa infection were selected for sputum collection. Efforts were made to simply 
the experiment by avoiding collection from patients who were infected with other bacteria such 
as burkholderia cepacia to simply the experiment. Sputum was pipetted in 200 µL alliquots and 
spread evenly onto the bottom of 24 transwell plate inserts. The insert was subsequently placed 
into a custom holder in a 100 mL specimen cup with 80 mL of 0.9% saline. 25 µg of tobramycin-
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polyphosphate coacverate or free tobramycin was spread across the top of the sputum and 
colony forming units were counted at 24 h. For CFU quantification sputum was resuspended in 
saline and removed from the transwell membrane. In a 10-fold dilution series, five 10 µL 
droplets were placed on agar plates and grown for 24 h at 37° C, after which the CFUs were 
counted. Since sputum samples contain a diverse microbiome, quantification was carried out for 
any gram negative strain against which aminoglycosides are particularly effective.  
 
5.2.8 Data processing and statistical analysis 
 
Data is reported as mean +/- 1 standard deviation with an n of 3. Mean and standard 
deviation was calculated using Microsoft Excel. Difference between means was tested for 
statistical significance using a one way ANOVA using IBM SPSS Statistical Analysis 24 software 
with a P value < 0.05 considered significant.  
 
5.3 Results 
5.3.1 Salt concentration and temperature affect coacervate 
 yield and form 
 Both NaCl concentration and temperature were explored for their effects on coacervate 
volume yield, transparency and phase state, either gel or coacervate. Coacervate yield was 
maximized at 0.9 M NaCl and decreased with either increasing or decreasing salt concentration, 
(Figure 5.4). Temperature did not have an effect on coacervate yield. At zero NaCl a dense gel 
was formed (Figure 5.3 D) and at 0.15 mM NaCl the coacervate remained cloudy (Figure 5.3 A) 
. Clear coacervates were formed with 0.3 M NaCl between 5° and 30° C and with 0.9-1.5 M NaCl 
between 5° and 35° C, Figure 5.3 B. Temperature above 35° C resulted in cloudy coacervates 
across all salt concentrations, 0.15 M to 1.5 M, Figure 5.4.   
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 NaCl concentration not only affects coacervate volume yield and form but also affected 
the amount of tobramycin in the dense coacervate phase. Tobramycin content was measured in 
the supernatant of pPEMA-MA and tobramycin coacervates across NaCl concentrations from 0 
to 1.2 M, Figure 5.5. The concentration of total tobramycin in coacervate and dilute phases was 
25 mg mL-1. At zero NaCl the tobramycin was concentrated primarily in the gel phase, 24 mg mL-
1, and decreased gradually to 20 mg mL-1 as NaCl concentration was increased to 0.9 M. 
Increasing NaCl concentration above 1 M resulted in more tobramycin remaining in the 
supernatant and only 9 mg mL-1 tobramycin in the coacervate at 1.2 M NaCl.  
 
5.3.3 Aerosolization of coacervate by traditional jet nebulization 
 
 The current clinical methods for pulmonary delivery tobramycin requires aerosolization, 
therefore, the same methods were employed for aerosolizing tobramycin-pPEMA-MA 
coacervates. Aerosolization was accomplished using a standard clinical jet nebulization system, 
Figure 5.6. Before aerosolization clear coacervates were shaken by hand to resuspend the 
coacervate into an emmulsion of micro-coacervate droplets, Figure 5.6, 5.3 C.  
Commercial jet nebulizers produce an aerosolized mist of particles between 1-5 µm and 
coacervate droplets can be nebulized in a similar size range as individual droplets or as smaller 
droplets contained in a larger droplet of dilute phase solution, Figure5.2. To assess droplet size 
prior to nebulization pre-aerosolized droplets were pipetted onto a glass slide immediately after 
resuspension and imaged using DIC microscopy. Using image J particle analyzer the droplet 
diamaters were calculated to be between 1 and 4 µm with the majority of droplets between 1 
and 2 µm, Figure 5.7 C.  
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To determine successful aerosolization of coacervate droplets, nebulized particles were 
lected on filter paper for 2 minutes and weighed to compare mass. Weight of aerosolized 
coacervate was 17.7 +/- 4 mg, free tobramycin 8.7 +/- 4 mg, and saline 7 +/- 2 mg, Figure 
5.6. There was significantly (P<0.05) more coacervate by weight nebulized versus aerosolized 
free tobramycin or 1 M saline, thus illustrating that the weight of material nebulized was not a 
result of free tobramycin or salt but in fact successful aerosilization of coacervate material.  
As an alternative method to verify successful coacervate aerosolization, fluorescently 
labeled pPEMA-MA was used to form tobramycin-pPEMA-MA coacervates and was 
subsequently aerosolized onto glass slides and imaged with fluorescent microscopy. Evaporation 
of water quickly left salt crystals on the slide which prevented un-obstructed visualization of the 
aerosolized coacervate film and determination of droplet size or film formation. However, the 
integrated intensity of the fluorescent images is directly correlated with the quantity of 
fluorescent signal from surface b coacervate. The normalized integrated intensity was 1.5 +/- 0.8 
for surfaces with labeled coacervate and 0.18 +/- 0.04 for surfaces with only aerosolized saline, 
Figure 5.8. 
5.3.4 In vitro release of tobramycin from coacervates 
The release kinetics of tobramycin from tobramycin pPEMA-MA coacervates was 
determined in both 150 mM saline and a more biolocically relevant solution of 130 mM NaCl, 
1.5 mM Mg2+ and 2.5 mM Ca2+. While polyphosphate-tobramycin coacervates dissolved 
completely within 48 h in 150 mM NaCl, they were stabilized in the presence of Ca2+ and Mg2+ 
due to formation of metal-phosphate complexes, which prevent dissociation of the coacervate. 
There was a corresponding sustained release of tobramycin as it exchanged with metal ions for 
up to 10 days. Immediately after replacing the dilute phase with a 130 mM NaCl, 1.5 mM Mg2+ 
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and 2.5 mM Ca2+ solution, the coacervate spontaneously re-suspended into a partly cloudy 
solution which was immediatly centrifuged to re-settle the coacervate phase. The quantity of 
tobramycin released was related to the thickness of the coacervate film. The initial 24 h release 
of tobramycin was 0.81 +/- 0.07, 1.08 +/- 0.05, and 1.35 +/- 0.02 mg for coacervates thickness of 
0.3, 0.6 and 1.2 mm respectively, Figure 5.9. Tobramycin release decreased gradually to close to 
zero release at day 12 regardless of coacervate thickness, Figure 5.9. After 12 days, cumulative 
tobramycin release was  2.3 +/- 0.16, 3.1 +/- 0.14, 3.9 +/- 0.21 mg for  coacervates thickness of 
0.3, 0.6 and 1.2 mm respectively. 
5.3.5 Efficacy against bacteria in CF sputum 
CFUs were counted before and after exposure of sputum to free tobramycin and 
tobramycin coacervate. After 24 h there was a reduction in CFUs from 570 CFU gram positive 
mL-1 sputum to 14 CFU gram positive mL-1 sputum with free tobramycin and 10 CFU gram 
positive mL-1 sputum with coacervate. At the same time point there was a corresponding drop in 
gram negative CFU’s from 5 CFU mL-1 sputum to 4 CFU mL-1 with free tobramycin and 1 CFU mL-1 
with tobramycin-coacervate. It is important to note that there was a significant reduction of 
CFU’s in all samples including the control over a 48 h time course.   
5.4 Discussion 
5.4.1  Factors effecting the yield, form and tobramycin content of 
pPEMA-MA coacervates 
Formation of clear coacervates is dependent on the type of polyions. Strong polyions 
trend toward precipitation while weak polyions form coacervates.31 For example, coacervates 
have been formed by weak interactions between negatively charged carboxyl groups and 
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charged residues in proteins such as B-lactoglobulin, whey protein, and albumin.39–45 On the 
other hand, precipitates, instead of coacervates, resulted from stronger interactions between 
sulfate or phosphate groups and proteins like albumin and whey protein.46–49 Preliminary work 
by Stewart and Song have shown that pPEMA-MA will form precipitates with Ca2+ and clear 
coacervates with Mg2+ an ion shown to form a weaker complex with phosphates.(unpublished) 
In pPEMA-pAAm hydrogels strong phosphate-Ca2+ crosslinks resulted in increased toughness 
while phosphate-Mg2+ crosslinks had much lower modulus and negligible work to fracture. The 
weakness of the Mg2+ bonds may be due in part to a higher affinity to retain an inner sphere 
hydration shell, a feature that may also assist in forming hydrated coacervates.34,50 Like Mg2+, 
tobramycin forms weak crosslinks in pPEMA-MA pAAm hydrogels, as evidenced by lower 
modulus and lack of yield (Chapter 4), and as a weak polyion also was shown to form clear 
coacervates with pPEMA-MA.  
Coacervates were formed with a 1:1 charge ratio between the charged phosphates on 
pPEMA-MA and primary amines on tobramycin. Maximizing coacervate yield has been linked to 
forming neutral complexes or complete charge balance, a result that has been verified with 
polyphosphate-tobrmaycin coacervates (unpublished).31  Both high and low NaCl concentrations 
have a general dissociative effect on complex formation, which explains the drop off in 
coacervate volume yield at salt concentrations higher or lower than 0.9 M NaCl, Figure 5.4. 
Lower salt concentration may result in electrostatic repulsive forces between charged 
phosphates while very high salt concentration shields these charges and may result in a 
shortened debye length, thus a reduction in complex formation.51 Alternatively, high salt may 
also reduce the entropic driving force through counter ion release for complex formation. 
Furthermore, while the lower salt coacervates have a reduced volume the state change from 
clear coacervate to gel may suggest a denser material that is a result of dense crosslinking and 
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gel formation. Tobramycin content was shown to be maximized at low salt and supports the 
argument that, at low NaCl concentrations, the coacervate volume decrease is a result of 
condensing into a gel versus formation of less coacervate.  Raising the salt concentration of 
beyond 1M NaCl results in less tobramycin in the dense coacervate phase due to increase 
charge screening and a reduction of tobramycin-pPEMA-MA complex formation. It is also 
possible that the presence of coacervate, when a majority of tobramycin remains in the dilute 
phase, may be driven by a salting out of the polymer from the dilute solution.52  
5.4.2  Coacervates can be aerosolized using traditional jet nebulization 
The current method for pulmonary delivery of tobramycin is jet nebulization of a 
solution of dissolved or unbound tobramycin. These devices use negative pressure arising from 
high-velocity gas, which draws liquid from a reservoir up a narrow opening or venturi where is it 
aerosolized, called the Bernoulli effect.53 The overall technology for jet nebulization has 
remained consistant since the 1940’s although recent designs by Pari LC® have increased 
efficiency.54,55 Efforts to directly aerosolize the dense caocervate phase using current 
nebulization techniques was unsuccessful due to the high viscosity and cohesive forces. To aid in 
nebulization coacervates were shaken by hand to re-suspend the dense coacervate phase into 
micro-droplets in the dilute phase, forming a tobramycin-pPEMA-MA coacervate emmulsion. 
These re-suspended micro coacervate droplets were imaged with DIC microscopy and had 
diameters between 1-4 µm with ~90% below 2 µm. These droplet sizes fall into the normal 
range for nebulized droplets (1-5 um) and it is expected that coacervate droplets are either 
directly aerosolized or aerosolized as contained in droplets of dilute phase solution.  
Re-suspended pPEMA-MA and tobramycin coacervates were successfully nebulized for 
pulmonary delivery as determined by both gravimetric data and fluorescent imaging. The 
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significantly (P<0.05) higher weight (+9 mg) of aerosolized coacervate material over tobramycin 
and 1M NaCl illustrates that the material aerosolized is due to coacervate complexes and not 
due to the salt content alone or from aerosolization of released or unbound tobramycin. In 
addition to increased aerosolized mass from nebulized coacervates fluorescein labeled 
coacervates were also nebulized and collected onto a glass slide as a film composed of collected 
aerosolized coacervate droplets. It is evident from fluorescent images and integrated pixel 
intensity that aerosolized droplets are collecting on the slide surface and merging to form a 
coacervate film. The significantly higher (P<0.01) integrated intensity of images of surfaces with 
labeled coacervate show successful nebulization of tobramycin-pPEMA-MA coacervate.  
5.4.3  Evidence for sustained release from polyphosphate- 
 
tobramycin coacervate films 
In the presence of divalent metal ions, coacervates are stabilized and have a sustained 
release profile with an initial bolus release followed by a slower release for up to 12 days. Initial 
replacement of the dilute phase with 150 mM NaCl and no divalent metal ions results in 
disruption of the equilibrium between dense and dilute phases and leads to dissolving of the 
coacervate within 48 h. However, in the presence of Ca2+ and Mg2+, the dense coacervate phase 
is stabilized as tobramycin is released and replaced with metal-phosphate bonds. This was 
evident in pPEMA-pAAm hydrogels where metal ions such as Mg2+, Ca2+, and Zn2+ were shown 
to crosslink phosphates in the hydrogel. Similarly, metal ions can crosslink phosphates in the 
coacervate with a subsequent transition from fluid coacervate to crosslinked gel. The metal 
crosslinked coacervate or gel does not dissolve and  leads to a sustained tobramycin release. 
The bolus release in the initial 24 h could be a result mixing that occurs during the first 
replacement of the dilute phase with the release solution. Divalent metal ions appear to initially 
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cause dispersion of the coacervate, increasing the interface area between the coacervate and 
release solution. Subsequent solutions changes did not result in any observable dispersion of 
the coacervate or change to solution transparency and the related tobramycin release was 
much lower than day 1. The quantity of tobramycin released in the first 24 h correlates with 
coacervate thickness with 0.81 +/- 0.07, 1.08 +/- 0.05, and 1.35 +/- 0.02 mg tobramycin for 
coacervates thickness of 0.3, 0.6, and 1.2 mm, respectively. This is expected, especially with an 
initial mixing event, that the tobramycin bolus release should increase with increasing mass of 
coacervate.  
After the first 24 h, daily release decreased steadily down to zero by day 12. The 
percentage of total tobramycin release is dependent upon coacervate thickness.  There is a 6%, 
10%, and 15% release of total payload for coacervates with 1.2, 0.6, and 0.3 mm thickness 
respectively, Figure 5.9. A similar pPEMA-MA and pAAm hydrogel showed sustained release of 
tobramycin over 70 days but only released ~5% of total loaded tobramycin.34 Both hydrogel and 
coacervate retain tobramycin through electrostatic interactions between phosphates and 
primary amine groups on tobramycin. Additionally, in both cases the release is suspected to be a 
gradual result of electrostatically reduced diffusion in combination with replacement by Ca2+ or 
Mg2+. It has been argued in Chapter 3 that release of tobramycin from pPEMA-pAAm hydrogels 
may occur primarily from the surface of the material with interior tobramycin experiencing an 
insurmountable electrostatic barrier to diffusion. This may explain the release profile from 
tobramycin coacervates. While the amount of tobramycin coacervate doubles from thickness of 
0.3 to 0.6 and from 0.6 to 1.2 mm the total drug release only increases by ~ 35% with most of 
the difference resulting from the initial bolus release, Figure 5.9. Additionally, since all 
coacervate samples have the same surface area and transition from fluid coacervate to gel in 
the presence of Ca2+, it is reasonable to suggest that tobramycin release between days 2 and 12 
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is primarily from the surface of the coacervate, while interior tobramycin experiences a steep, 
electrostatic barrier to diffusion. This would explain the disproportionate increase to release 
tobramycin with increasing coacervate thickness and aligns with observations from tobramycin 
loaded hydrogels.  
5.4.4 Reduction of bacteria in CF sputum by exposure to polyphosphate- 
 
tobramycin coacervate 
Quantification of colony forming units from CF sputum showed a reduction in gram 
positive CFUs from 570 to 14 CFU uL-1 sputum for free tobramycin and 10 CFU uL-1 sputum for 
tobramycin coacervates. There was also a reduction in gram negative bacteria from 50 CFU uL-1 
sputum to 4 and 1 with unbound tobramycin and tobramycin-coacervate respectively. In both 
cases, the coacervate samples were marginally more effective than free tobramycin. However, it 
is important to note that the control sample also saw a reduction in CFUs from 570 CFU uL-1 
sputum to 54. This suggests some external event or environmental factor, which prevented 
growth of the bacteria. There are several potential sources for this observation: one, decreasing 
CFU count may have resulted from the freezing or storage process of sputum samples; two, 
sputum samples were taken from a patient on a current cycle of tobramycin. Prior preliminary 
experiments with fresh sputum showed little to no reduction of bacterial CFU’s in sputum 
samples in a similar experimental set up over a 24 h time point. This could mean that the 
current results have discounted the sustained release of tobramycin from the coacervates 
because the bacteria in the unbound tobramycin sample was not capable of growing once the 
antibiotic had diffused out of the system. These results warrant further experimentation with 
fresh sputum samples and use of more stringent patient selection criteria to select only patients 
at least a week or two removed from their last tobramycin cycle. Additionally, progress can be 
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made by using tobramycin-coacervate in chronic pulmonary infection rat models or CF animal 
models.  
5.5 Conclusions 
Spontaneous coacervation between negatively charged polyphosphate polymer and 
positively charged tobramycin results in a phase separation into two aqueous layers, where 
tobramycin and polyphosphate polymer is concentrated into a dense coacervate phase. This 
tobramycin rich dense phase can easily be re-suspended, by simple vortexing, into an emulsion 
of micro droplets that are then readily aerosolized using current, standard nebulization 
equipment. Characterization of the coacervation process including NaCl concentration and 
temperature has revealed optimal synthesis conditions and a corresponding in vitro release 
assay has illustrated the materials potential for sustained delivery to tobramycin. Furthermore, 
initial tests of coacervate against bacteria in CF sputum show that coacervate particles 
successfully penetrate and deliver bactericidal levels of tobramycin. While it is unclear yet if 
there is significant improvement over the current state of the art, in terms of total infection 
eradication, the in vitro release assays show a prolonged release action, which can lead to a 




Figure 5.1: Schematic of tobramycin-polyphosphate coacervate formation. A) Starting materials 
consist of pPEMA-MA and tobramycin at initial concentrations of 50 mg mL-1 and pH 7.7. B) 
Combining both materials produces a liquid-liquid phase separation or coacervate. The dilute 
phase is shown in purple and the dense coacervate phase in blue.  
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Figure 5.2: Photographs of coacervates to determine form and flow. NaCl concentration effects 
the transparency of coacervate: A) low salt (150 mM NaCl) resulted in cloudy coacervate, B) 
higher salt (1 M NaCl) results in a clear coacervate. C) Clear coacervates can be re-suspended 
into an emulsion of micro-coacervate droplets. D-F) The flow rate of coacervates is dependent 
on NaCl concentration: D) minimal flow in the gel-like coacervate with 150 mM NaCl, the flow 
rate increases with increasing NaCl concentration E) 500 mM NaCl and F) 1 M NaCl.  
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Figure 5.3: Four dimensional phase diagram for coacervate yield and form with varying salt 
concentration and temperature. Phase is gel (blue), cloudy (red) or clear (green). Total 
coacervate yield is presented as a percentage of total volume. Clear, fluid coacervates (area in 





Figure 5.4: Effect of NaCl concentration on amount of tobramycin (mg/mL) in the dense 
coacervate phase (red) and dilute equilibrium phase (black). The crossover point between 1 M 




Figure 5.5: Gravimetric assessment of coacervate aerosolization. The weight of nebulized 
materials is significantly higher for coacervate sample versus free tobramycin and a 1 M NaCl 







Figure 5.6: Schematic of coacervate resuspension and subsequent nebulization using a 
traditional jet nebulizer system. Dense coacervate is shown in dark blue and is easily 
resuspended into the dilute phase by shaking, shown in light blue. The coacervate suspension is 
placed into a nebulizer reservoir and aerosolized using high velocity gas jet and capillary. The 
resulting aerosolization should produce droplets between 1 and 5 µm diameter. 
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Figure 5.7: Coacervates can be resuspended into microdroplets with diameters less than 5 µm. 
A) DIC image of coacervate droplets within 1 minute of resuspension of coacervate droplets. B)
DIC image after 8 bit conversion, thresholding and was used for particle size analysis. C)
Histogram of droplet size from automated particle size analyzer function in Image J. Droplet
diameter should be less than 5 µm for efficient aerosolization in the jet nebulizer system.
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Figure 5.8: Fluorescently labeled pPEMA-MA tobramycin coacervates were aerosolized and 
collected on a glass slide. The integrated intensity of these images were compared between 
aerosolized coacervates and 1 M NaCl saline. The increased integrated intensity for the 
coacervate images indicated successful aerosolization of pPEMA-MA. Error bars are +/- 1 S.D., 




Figure 5.9: In vitro release of tobramycin from polyphosphate coacervates. A) Daily release of 
tobramycin from coacervate films of varying thickness, Red: 1.2 mm, Blue 0.6, and Black 0.3. B) 
Cumulative release of tobramycin summed from the daily tobramycin release data. Error bars 
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CHAPTER 6 
CONCLUSION 
6.1   Study discussion 
The mechanical characterizations of polyphosphate and metal ion hydrogels has re- 
affirmed the importance of phosphate-metal complexes as a natural toughening mechanism. 
Simple inclusion of this feature into a synthetic polyphosphate hydrogel, as discussed in this 
dissertation, resulted in a replication of caddisfly silk mechanics including increased modulus with 
a defined pseudo-yield point. The yielding behavior has been conclusively linked to the 
presence of phosphate-metal complexes as the yield height can be modulated based on metal 
ion identity or eliminated after removal of metal ions with EDTA treatment. The serial regions of 
phosphate- Ca2+ in caddisfly silk, as well as the polyphosphate hydrogels, rupture following a 
critical stress resulting in large strain hysteresis and energy dissipation. The reversible Ca2+-
phosphate complexes are reformed during recoil and can completely recover the mechanical 
potential within 90 m for tensile tests or 30 m for compression. Furthermore, the strength and 
toughness of caddisfly inspired hydrogels compares favorably with other synthetic double 
network hydrogel discussed in chapter 2. The initial modulus of Ca2+ loaded gels were within the 
upper range of other DN hydrogels and Zn2+ loaded gels exceeded the stiffness of other 
compared hydrogels. Moreover, the toughness of polyphosphate-metal hydrogels was much 
greater than other hydrogels which derive toughness from great extensibility and not increased 
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modulus and yield behavior. As a result, the caddisfly inspired hydrogels are more suitable as 
mechanical replacements for soft structural tissues, which do not operate under such extreme 
strains. 
Replacement of Ca2+ with tobramycin aminoglycosides resulted in a hydrogel densely 
crosslinked with tobramycin. Tobramycin loaded hydrogels in an in vitro solution with biologically 
relevant levels of Ca2+ and Mg2+ will gradually release tobramycin for up to 70 days. This in vitro 
release assay was further verified by placing tobramycin loaded hydrogels on a daily lawn of fresh 
P. aeruginosa where there was a measurable ZOI for 25 days. In addition to sustained ZOI
formation tobramycin loaded hydrogels were used to totally eradicate P.aerugionsa biofilms 
within 48 h in a biomimetic flow cell. While tobramycin incorporation into the polyphosphate 
hydrogel had an impactful effect on bacterial eradication, tobramycin crosslinks were much 
weaker than the previous phosphate-metal complexes and as a result there was a related loss in 
hydrogel toughness. Since the polyphosphate hydrogels exhibited an ability to eradicate 
P.aeruginosa biofilms by releasing only 5% of the total tobramycin payload it was conceivable
that combining metal ions with lower amounts of loaded tobramycin could eradicate biofilms 
while maintaining hydrogel toughness. 
It is important to note that this dissertation explores an uncharted area of hydrogel design 
by incorporating both phosphate-metal complexes in combination with phosphate-tobramycin 
crosslinks for a dual mechanism for toughening and sustained aminoglycoside release. It was 
shown that inclusion of tobramycin crosslinking into a polyphosphate-Ca2+ hydrogel maintained 
the sustained release profile for up to 60 days. While there was a reduction in modulus (~0.4 MPa) 
and strength at 80% compression (0.8 MPa), the mechanical properties were sufficient for 
inclusion of the hydrogel as a cartilage replacement material or in total joint replacement surgery 
as a structural component or spacer. 
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Finally, the dissertation has presented a complex coacervate of polyphosphate polymer 
and tobramycin for use as a pulmonary delivery vehicle for sustained tobramycin release to 
combat chronic CF infection. This work may present the most impactful future application for 
these materials due to a lack of any current clinical options for total eradication of P.aerugionsa 
infection in CF patients. Furthermore, current efforts to improve delivery of tobramycin have 
centered on improvements to nebulization equipment. For example, some drugs, such as 
Aztrozeonam, are used with newer vibrating mesh nebulizers which dramatically increase 
efficiency and decrease treatment time. However, these newer devices require more frequent 
dosing and therefore an increased risk of poor compliance. There is an opportunity for a new 
delivery product that increases efficiency and increases compliance, and the tobramycin- 
polyphosphate coacervates fit this role. 
6.2   Future work 
6.2.1 Development of an antibiotic releasing, underwater, 
pressure sensitive tape 
The works presented here have explored applications for the phosphate-metal complex 
toughening mechanism but have ignored the silk’s underwater adhesive properties. The caddisfly 
silk is comprised of not only a viscoelastic, energy dissipating core but also an adhesive outer layer 
that has been thoroughly explored by Ching-Shuen Wang and Russel Stewart et. al.1,2 Caddisfly 
silk has a fuzzy, adhesive peripheral layer that is present along the silk fiber, even inside the silk 
gland. The adhesive layer of the caddisfly silk is remarkably stable and, unlike terrestrial butterfly, 
moth or silk worm silk, is not easily stripped with detergents. Adhesion is proposed to occur in 
two steps. First, initial adhesion occurs from interactions between the peripheral glycoprotein 
layer and the surface. These initial interactions could be polymer-polymer entanglement or 
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physical crosslinking with surface absorbed macromolecules. Negative carbohydrate components 
could also interact with the surface electrostatically. Sugar –OH groups might also  participate in 
surficial hydrogen bonding. Second, peroxinectin in the peripheral layer crosslinks tyrosine 
residues in the peripheral with phenolic groups absorbed on a surface. Such a complex form of 
adhesion may not be necessary as pPEMA-pAAm hydrogels could incorporate a surface layer of 
very low crosslinked hydrogel to provide an adhesive interface. It may also be possible to explore 
polyphosphate hydrogel adhesion to calcium rich bone matrix. Over time phosphates in the 
hydrogels could complex with calcium phosphates like hydroxyapatite in bone, leading to a stable 
adhesion.3 
6.2.2 Hydrogels with dual delivery of drugs and synergistic molecules may 
improve clinical outcomes 
A general principle in eradication of difficult infections is that the application of multiple 
antibiotics is more successful than single antibiotic use. Future work can include design of 
polyphosphate hydrogels that sustain the release of tobramycin in combination with other 
antimicrobials to produce a synergistic effect. Synergistic effects can be determined by isolating 
the CFU reduction from each single antimicrobial component and comparing with total CFU 
reduction from the combination. If the CFU reduction of the combination is greater than the sum 
of the individual components it would be considered a synergistic effect versus only additive.4 
6.2.3 Delivery of copper-tobramycin complex to promote ROS 
or reduce inflammation 
Copper has been identified as a cofactor to enhance the effectiveness of tobramycin 
although there is some disagreement as to the specific action of a copper-tobramycin complex. 
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Kozlowski et. al. claimed copper has been shown to complex at several binding sites on 
tobramycin and can accentuate its antimicrobial properties by promoting formation of free 
radicals or reactive oxygen species (ROS).6 On the other hand, J.K. Shute et. al. have reported 
the Cu-Tobramycin complex as acting as an anti-inflammatory and antioxidant by removing 
ROS.7 Future work may perhaps incorporate polyphosphate propensity for binding metal ions 
into a delivery device for copper-tobramycin, which may help shed light into the role this 
complex as an antimicrobial or as an anti-inflammatory agent. 
6.2.4 Delivery of metabolites in combination with tobramycin to 
eliminate persister cells 
Nutritional gradients across the biofilm results in starvation driven antibiotic tolerance, 
where cells at the surface consume the majority of resources while underlying cells become 
inactive and less susceptible.8 Providing nutrients and metabolites to the population has been 
shown to accentuate the effectiveness of aminoglycosides. This could stem from cells reverting 
back to an aerobic form of metabolism or from contributions to the energy dependent step of 
aminoglycoside uptake. Metabolites such as glucose, fructose, mannitol and pyruvate might be 
delivered by passive diffusion from hydrogels or coacervate particles in accompaniment with 
tobramycin. 9 This approach has shown promise but is accompanied by increased risk to patient 
health. By increasing active bacterial cells there is increased risk of sepsis. Polyphosphate 
hydrogels have the potential to locally deliver a short burst of metabolites in combination with 
long term aminoglycoside release, which can kill bacterial cells as they become active and thereby 
reduce potential adverse effects to patient health. 
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6.2.5 Delivery of multiple antibiotic agents 
Anti-pseudomonas penicillin’s, such as piperacillin and carbenicillin, are recommended in 
combination with aminoglycosides, both to increase success of eradication and to prevent 
formation of drug resistant populations.10 Anwar et. al. showed a synergistic effect of attacking 
mucosal pseudomonas with a 2:1 piperacillin to tobramycin ratio.11 In the polyphosphate system, 
non-charged penicillin may diffuse from coacervates or gels in under a week, similar to the 
vancomycin release in chapter 4, followed by a prolonged release of tobramycin. Release of both 
drugs can be quantified using HPLC at various time points to determine a dual antibiotic release 
profile from the polyphosphate hydrogel or coacervate. 
In addition to multiple antibiotic release, DNase drugs can also be included in a 
polyphosphate delivery system to aid in cleavage of DNA, an important contributor to mucosal 
viscosity. DNase drugs are frequently used to facilitate greater mucous clearance as well as 
supporting particle adhesion and penetration.12 Furthermore, negatively charged regions in DNA 
are suspected of ensnaring positively charged aminoglycoside molecules thus preventing bacterial 
uptake.13 The combination of a DNase such as dornase alfa and tobramycin could be tested for 
synergistic effects and may possibly be a less time consuming vehicle for delivering tobramycin in 
conjunction with mucolytics leading to improved patient compliance. 
6.2.6 Using hydrogels to increase oxygen availability and increase ROS 
Formation of free radicals is a shared effect of many antibiotics and has been shown to 
contribute to a common pathway of microbial death.14–16 In benchtop experiments, increased 
availability of oxygen at the surface of a bacterial population is sufficient to enhance antibiotic 
effectiveness.17 This suggests that an increase in ROS has meaningful effects on eradication that 
could be tested with a combination of tobramycin and hydrogen peroxide. Hydrogen peroxide 
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could be loaded into polyphosphate hydrogels or coacervates at 1 mM, which has been shown to 
be high enough to induce cell death.18 Free radical concentration could be quantified using 
hydroxyphenyl fluorescein dye following published methods.16,19 In this case, future efforts would 
also need to monitor the effects of 1 mM hydrogen peroxide on polyphosphate polymer by 
looking for changes in NMR and ATR-FTIR spectras that can indicate changes in structure including 
loss of phosphate groups. 
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